[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 151
1. Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ: Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol; 2008 Sep;32(9):1299-309
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomas involving the breast account for approximately 2% of extranodal and <1% of all non-Hodgkin lymphomas.
  • The study group included 106 patients with breast lymphoma (105 women and 1 man).
  • In the localized group, diffuse large B-cell lymphoma (DLBCL) was most frequent (n=32, 64%).
  • In the disseminated group, follicular lymphoma was most frequent and exclusive to this group (P=0.0004).
  • A variety of other types of B-cell and T-cell non-Hodgkin lymphomas and classical Hodgkin lymphoma involved the breast at much lower frequency; most of these neoplasms involved the breast as part of disseminated disease.
  • In the disseminated group, patients with DLBCL had a worse disease-free survival compared with patients with mucosa-associated lymphoid tissue lymphoma or follicular lymphoma (P=0.01).
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / pathology. Lymphoma / classification. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / classification. Breast Neoplasms, Male / pathology. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636016.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, Salles G, Groupe d'Etude des Lymphomes de l'Adulte: Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol; 2007 May 1;25(13):1732-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
  • PURPOSE: Approximately 15% of patients with localized and 30% with disseminated classical Hodgkin's lymphoma fail to respond or relapse after first-line treatment.
  • PATIENTS AND METHODS: We prospectively analyzed the prognosis value of plasma levels of tumor necrosis factor (TNF), its soluble receptors TNF-R1 and TNF-R2, IL-10, IL1-RA, IL-6, and soluble CD30 (sCD30) when taken before any treatment in 519 consecutive patients with a first diagnosis of classical Hodgkin's lymphoma.
  • CONCLUSION: Plasma cytokine signature is sufficient to predict disease-related outcome in classical Hodgkin's lymphoma, and allows the identification of patients with very high risk of treatment failure.
  • [MeSH-major] Cytokines / blood. Hodgkin Disease / blood. Receptors, Cytokine / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Multivariate Analysis. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Cytokine
  •  go-up   go-down


3. Huang X, van den Berg A, Gao Z, Visser L, Nolte I, Vos H, Hepkema B, Kooistra W, Poppema S, Diepstra A: Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients. PLoS One; 2010;5(5):e10865
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients.
  • BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients.
  • [MeSH-major] Asian Continental Ancestry Group. Histocompatibility Antigens Class I / immunology. Histocompatibility Antigens Class II / immunology. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. China. Female. Herpesvirus 4, Human / immunology. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Netherlands. RNA, Viral / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2002 Aug 15;169(4):2172-9 [12165547.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Methods. 2003 Mar;29(3):227-35 [12725788.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] J Immunol. 1986 Oct 1;137(7):2299-306 [3760563.001]
  • [Cites] Blood. 1996 May 1;87(9):3844-51 [8611711.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):614-8 [9259400.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1020-30 [9680372.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2477-83 [9746788.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):685-91 [18245527.001]
  • [Cites] Tissue Antigens. 2008 Mar;71(3):219-26 [18257895.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5869-85 [18836468.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):528-36 [19017177.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7195-9 [12499257.001]
  • (PMID = 20526359.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC2878318
  •  go-up   go-down


Advertisement
4. Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML: Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica; 2006 May;91(5):596-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (HL) are derived from different cell types, namely T cells and B cells, respectively.
  • DESIGN AND METHODS: In this study, the transcriptional profiles of ALCL cell lines, primary ALCL tumor cells from peripheral blood and HL cell lines were compared to each other and to normal B-cell subsets, B non-Hodgkin's lymphomas (NHL) and B NHL- and Epstein-Barr virus (EBV)-transformed B-cell lines in order to establish their relationship at the transcriptional level and to identify genes with possible pathobiological impact.
  • INTERPRETATION AND CONCLUSIONS: At a transcriptional level HL is more closely related to Alk+ ALCL than to the B-NHL or B-cell samples investigated, although it is a B-cell derived lymphoma.
  • [MeSH-major] Gene Expression Profiling. Hodgkin Disease / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Transcription, Genetic
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Cell Line, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Leukemia / blood. Leukemia / genetics. Leukemia / metabolism. Leukemia / pathology. Lymphoma / classification. Lymphoma / genetics. Lymphoma / metabolism. Lymphoma / pathology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. RNA, Complementary / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670065.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


5. Mitarnun W, Suwiwat S, Pradutkanchana J: Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev; 2006 Jan-Mar;7(1):91-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
  • Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma.
  • In our previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin's lymphoma (cHL), 51% of non-Hodgkin's lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin's lymphoma, B-cell (NHL-B) were EBV-related.
  • In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin's lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin's lymphoma of the nasopharynx (e-NHL-NP) in Southern Thailand, between 1997 and 2004.
  • The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant lymphoma were 3.7% and 6.8%, respectively.
  • Monoclonal bands of the TCR-gamma gene were detected in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma.
  • The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the germline configuration of the TCR genes.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Nasopharyngeal Neoplasms / virology. Paranasal Sinus Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. DNA, Viral / analysis. Female. Humans. In Situ Hybridization. Incidence. Lymph Nodes / pathology. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Rate. Thailand / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629523.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


6. Knecht H, Sawan B, Lichtensztejn Z, Lichtensztejn D, Mai S: 3D Telomere FISH defines LMP1-expressing Reed-Sternberg cells as end-stage cells with telomere-poor 'ghost' nuclei and very short telomeres. Lab Invest; 2010 Apr;90(4):611-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Epstein-Barr virus (EBV) negative Hodgkin's cell lines and classical EBV-negative Hodgkin's lymphoma (HL), Reed-Sternberg cells (RS cells) represent end-stage tumor cells, in which further nuclear division becomes impossible because of sustained telomere loss, shortening and aggregation.
  • We performed a 3D telomere analysis after quantitative fluorescent in situ hybridization on 5 mum tissue sections on two LMP1-expressing HL cases and showed highly significant telomere shortening (P<0.0001) and formation of telomere aggregates in RS cells (P<0.0001), when compared with the mononuclear precursor Hodgkin cells (H cells).
  • [MeSH-major] Hodgkin Disease / genetics. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Female. Humans. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Male. Viral Matrix Proteins / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142802.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


7. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • All were cases of classical HL with 60% being of the mixed cellularity (MC) subtype.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD15 / immunology. Antigens, CD30 / immunology. Biomarkers, Tumor / immunology. Child. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Immunophenotyping. Male. Nigeria. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


8. Azambuja D, Lossos IS, Biasoli I, Morais JC, Britto L, Scheliga A, Pulcheri W, Natkunam Y, Spector N: Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. Leuk Lymphoma; 2009 Nov;50(11):1830-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma.
  • The human germinal center-associated lymphoma (HGAL) gene has prognostic value in diffuse large B-cell lymphoma, and expression of its cognate protein is germinal center-specific.
  • A previous study had suggested that HGAL protein expression might also be related to the outcome in patients with Hodgkin lymphoma (HL).
  • This study confirms and validates recent findings of a correlation between HGAL expression and outcome in classical HL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 2003 Jan 15;101(2):433-40 [12509382.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1668-80 [18798102.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] Blood. 2007 Jan 1;109(1):298-305 [16954503.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 9:ix71-9 [17631599.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4268-77 [17823310.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • (PMID = 19883310.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U56 CA112973; United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA109335-04A1; United States / NCI NIH HHS / CA / R01 CA109335-04A1; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GCET2 protein, human; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS207132; NLM/ PMC2882884
  •  go-up   go-down


9. Tamaru J, Tokuhira M, Nittsu N, Nakamura S, Ichinohasama R, Suzuki R, Mori H, Takagi T, Suzuki T, Itami J, Itoyama S, Mikata A: Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1127-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma.
  • In the WHO classification, the majority of Hodgkin-like ALCL cases as defined by the REAL classification are considered to be CHL.
  • Among specimens of Hodgkin-like ALCL and ALK-negative ALCL, expression of PAX-5/BSAP was observed in 77% (20/26) and 18% (3/17), respectively.
  • Our results may support the WHO classification in which most cases of Hodgkin-like ALCL are classified as CHL.
  • However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. B-Cell-Specific Activator Protein / genetics. Biomarkers, Tumor / genetics. Diagnosis, Differential. Female. Gene Expression Regulation, Leukemic. Humans. Male. Middle Aged. Neoplasm Staging. Octamer Transcription Factor-2 / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Survival Analysis. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577776.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-2; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Trans-Activators; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


10. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A: Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol; 2005 Aug 20;23(24):5739-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
  • PURPOSE: To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-rich classical Hodgkin's lymphoma (LRCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: From a total of 2,715 patients with biopsy-proven HL treated within the trials HD7 to HD12 of the German Hodgkin's Study Group, 100 patients (4%) with LRCHL, 145 patients (5%) with lymphocyte-predominant HL (LPHL), 1,688 patients (62%) with nodular sclerosis, 731 patients (27%) with mixed cellularity, and 23 patients (1%) with lymphocyte depletion were identified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease Progression. Female. Germany. Humans. Lymphocytes. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 May 10;24(14):2220
  • (PMID = 16009944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Eckerle S, Brune V, Döring C, Tiacci E, Bohle V, Sundström C, Kodet R, Paulli M, Falini B, Klapper W, Chaubert AB, Willenbrock K, Metzler D, Bräuninger A, Küppers R, Hansmann ML: Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia; 2009 Nov;23(11):2129-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
  • Anaplastic large cell lymphoma (ALCL) is a main type of T-cell lymphomas and comprises three distinct entities: systemic anaplastic lymphoma kinase (ALK) positive, systemic ALK(-) and cutaneous ALK(-) ALCL (cALCL).
  • Little is known about their pathogenesis and their cellular origin, and morphological and immunophenotypical overlap exists between ALK(-) ALCL and classical Hodgkin lymphoma (cHL).
  • We conducted gene expression profiling of microdissected lymphoma cells of five ALK(+) and four ALK(-) systemic ALCL, seven cALCL and sixteen cHL, and of eight subsets of normal T and NK cells.
  • The analysis supports a derivation of ALCL from activated T cells, but the lymphoma cells acquired a gene expression pattern hampering an assignment to a CD4(+), CD8(+) or CD30(+) T-cell origin.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. Lymphoma, Large-Cell, Anaplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line. Female. Humans. Immunohistochemistry. Killer Cells, Natural / cytology. Killer Cells, Natural / physiology. Male. Microdissection. Middle Aged. NF-kappa B / metabolism. Phenotype. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes / cytology. T-Lymphocytes / physiology. Young Adult


12. García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA: Large B-cell lymphoma with Hodgkin's features. Histopathology; 2005 Jul;47(1):101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with Hodgkin's features.
  • AIMS: To describe the features of a series of nine cases of diffuse large B-cell lymphoma (DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's lymphoma (HL).
  • Histopathologically, tumours showed diffuse large cell areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
  • Immunophenotypically, tumours shared features of DLBCL and classical HL, with expression of CD30, CD15 (6/9), and a full B-cell profile including CD45RB, CD20, CD79a and OCT2.
  • Finally, 2/9 cases showed 3q27 (BCL6) rearrangement, and 1/9 had p53 gene mutations, both of which are rarely detected in classical HL.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982329.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. Salipante SJ, Mealiffe ME, Wechsler J, Krem MM, Liu Y, Namkoong S, Bhagat G, Kirchhoff T, Offit K, Lynch H, Wiernik PH, Roshal M, McMaster ML, Tucker M, Fromm JR, Goldin LR, Horwitz MS: Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A; 2009 Sep 1;106(35):14920-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells.
  • Classical Hodgkin lymphoma (cHL) is a malignancy of B-cell origin in which the neoplastic cells, known as "Reed-Sternberg" (RS) cells, are characteristically binucleated.
  • The translocation disrupts KLHDC8B, an uncharacterized gene from a region (3p21.31) previously implicated in lymphoma and related malignancies, resulting in its loss of expression.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4188-98 [10825184.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1125-34 [19176389.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5365-70 [11034072.001]
  • [Cites] Blood. 2001 Feb 1;97(3):818-21 [11157505.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17484-96 [11278705.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Acta Microbiol Immunol Hung. 2002;49(1):69-80 [12073827.001]
  • [Cites] J Hum Genet. 2002;47(9):453-9 [12202982.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):193-203 [12353262.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44140-6 [12213805.001]
  • [Cites] BMC Bioinformatics. 2003 Sep 17;4:42 [13678422.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1972-4 [15026332.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Science. 2004 Jul 2;305(5680):61-6 [15166316.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Science. 2004 Oct 29;306(5697):876-9 [15375219.001]
  • [Cites] Science. 1979 Mar 9;203(4384):1027-9 [424728.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Methods Cell Biol. 1991;35:3-35 [1779860.001]
  • [Cites] Cell. 1993 Mar 12;72(5):681-93 [8453663.001]
  • [Cites] Genes Dev. 1994 Jun 15;8(12):1434-47 [7926743.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):307-16 [9322893.001]
  • [Cites] Am J Hum Genet. 1997 Nov;61(5):1179-88 [9345087.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3042-7 [9501212.001]
  • [Cites] Pharmacogenomics J. 2005;5(2):81-8 [15668732.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1735-9 [15774750.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4553-60 [15728122.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] EMBO J. 2005 Sep 7;24(17):3000-11 [16107882.001]
  • [Cites] Biochimie. 2005 Sep-Oct;87(9-10):805-11 [15951098.001]
  • [Cites] Novartis Found Symp. 2005;269:59-66; discussion 66-72, 223-30 [16355535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3304-9 [16492737.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):764-80 [17050074.001]
  • [Cites] Nature. 2007 Mar 15;446(7133):329-32 [17361185.001]
  • [Cites] Dev Cell. 2007 Jun;12(6):887-900 [17543862.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7283-301 [17533367.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Cell. 2007 Nov 30;131(5):847-60 [18045532.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1303-9 [18316592.001]
  • [Cites] BMJ. 2000 May 27;320(7247):1468 [10827061.001]
  • (PMID = 19706467.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP55506; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CP / N02-CP-55506; United States / NIA NIH HHS / AG / F30 AG030316; United States / NIA NIH HHS / AG / F30AG030316
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC2736436
  •  go-up   go-down


14. Möller P, Mader A, Barth TF, Brüderlein S: [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma]. Pathologe; 2008 Nov;29 Suppl 2:317-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma].
  • [Transliterated title] U-HO1. Eine neue Zelllinie, abstammend von einem primär therapierefraktären klassischen Hodgkin-Lymphom.
  • The Hodgkin cell line U-HO1 was established from a malignant pleural effusion of a 23-yr-old male patient during the end stage of refractory nodular sclerosing classical Hodgkin lymphoma (cHL).
  • [MeSH-major] Cell Line, Tumor. Hodgkin Disease / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Allelic Imbalance / genetics. Cell Division / genetics. Cell Division / physiology. Chromosomes, Human, Pair 2 / genetics. Combined Modality Therapy. Drug Resistance, Neoplasm / genetics. HLA-D Antigens / analysis. Humans. Male. Phenotype. Reed-Sternberg Cells / pathology


15. Barakzai MA, Pervez S: CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):6-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity.
  • BACKGROUND: It is now well established that Hodgkin cells are clonal B cells with a CD30 and CD15 phenotype.
  • However, on immunohistochemistry, in our experience and the experience of others, CD20 positivity in an otherwise typical classical Hodgkin's Lymphoma is not uncommon and if associated with CD15 negativity poses a potential diagnostic trap and is likely to be called B-NHL.
  • OBJECTIVE: To assess the frequency of B-cell related antigens CD20 and CD79a in classical Hodgkin's Lymphoma.
  • MATERIALS AND METHODS: A total of 91 consecutive cases of classical Hodgkin's Lymphoma were analyzed for co-expression of CD20 and CD79a.
  • All cases of nodular lymphocyte predominant Hodgkin's Lymphoma were excluded.
  • RESULTS: All 91 cases of classical Hodgkin's Lymphoma showed negativity for LCA and positivity for CD30.
  • CD15 negativity with CD20 positivity was seen in 7 (7.7%) cases of otherwise typical classical Hodgkin's Lymphoma.
  • CONCLUSIONS/RECOMMENDATIONS: CD20 expression is frequent in classical Hodgkin's Lymphoma and our results are in consensus with reported literature on this subject.
  • [MeSH-major] Antigens, CD20 / analysis. B-Lymphocytes / chemistry. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Antigens, CD79 / analysis. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136769.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Antigens, CD79; 0 / CD79A protein, human; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


16. Takach S, Yang L, Ho J, Sabri E, Martin L, Halpenny M, Atkins H, Sabloff M, McDiarmid SA, Huebsch LB, Bence-Bruckler I, Giulivi A, Allan DS: Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation. Bone Marrow Transplant; 2010 May;45(5):856-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation.
  • Autologous peripheral blood stem cell transplantation (PBSCT) for Hodgkin lymphoma (HL) is curative for many patients with relapsed or refractory disease.
  • Neoplastic transformation of B-lymphocytes probably underlies the development of classical HL.
  • [MeSH-major] B-Lymphocytes / immunology. Clone Cells / immunology. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Male. Recurrence. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767777.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


17. Trimèche M, Bonnet C, Korbi S, Boniver J, de Leval L: Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study. Leuk Lymphoma; 2007 Jul;48(7):1323-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study.
  • The association between Epstein-Barr virus (EBV) and classical Hodgkin's lymphoma (cHL) varies according to the geographic location.
  • [MeSH-major] Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Viral Matrix Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Belgium / epidemiology. Child. Epstein-Barr Virus Infections / diagnosis. Female. Humans. Male. Middle Aged. Palatine Tonsil / virology. Prevalence. Reed-Sternberg Cells / virology. Risk Factors. Sequence Deletion

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613761.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


18. Ohsawa M, Fukushima H, Ikura Y, Inoue T, Shirai N, Sugama Y, Suekane T, Kitabayashi C, Nakamae H, Hino M, Ueda M: Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma; 2006 Sep;47(9):1863-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.
  • Although many studies have revealed the association between cyclooxygenase-2 (COX-2) and carcinogenesis, the association between COX-2 and Hodgkin's lymphoma (HL) remains unknown.
  • Hodgkin and Reed - Sternberg (HRS) cells with COX-2 expression were scored as 0 = no staining; 1 = <25% of cells staining; 2 = 25-49%; 3 = 50-75%; and 4 = > or =75%.
  • COX-2 expression was observed in 15 cases of classical HL.
  • [MeSH-major] Cell Proliferation. Cyclooxygenase 2 / metabolism. Hodgkin Disease / enzymology. Membrane Proteins / metabolism. Neovascularization, Pathologic. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064999.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


19. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • In contrast to the classical HL, the 10-year prognosticated overall survival rate was 100 vs. 82%, the event free survival was: 75% vs. 70%.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):146-50 [16729353.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):184-9 [17591565.001]
  • [Cites] Acta Haematol. 1986;76(1):29-32 [3098024.001]
  • [Cites] Orv Hetil. 2002 Mar 31;143(13):651-61 [11975042.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):195-202 [12242134.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):787-804 [17908620.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S45-56 [9926237.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):897-914 [17908627.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Birgersdotter A, Baumforth KR, Porwit A, Sjöberg J, Wei W, Björkholm M, Murray PG, Ernberg I: Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer; 2009 Oct 20;101(8):1393-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.
  • BACKGROUND: Classical Hodgkin's lymphoma (cHL), although a malignant disease, has many features in common with an inflammatory condition.
  • [MeSH-major] Gene Expression Profiling. Hodgkin Disease / classification. Hodgkin Disease / pathology. Inflammation / pathology. Wound Healing
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers. Extracellular Matrix / metabolism. Female. Fibrosis. Humans. Immunohistochemistry. Male. Middle Aged


21. Atayar C, van den Berg A, Blokzijl T, Boot M, Gascoyne RD, Visser L, Poppema S: Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments. J Clin Pathol; 2007 Oct;60(10):1092-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.
  • BACKGROUND: Hodgkin's lymphoma (HL) is characterised by an ineffective immune response that is predominantly mediated by CD4+ T-cells.
  • In classical HL (CHL), which is generally located in the interfollicular zones, a predominance of T-bet+ T-cells and lesser amounts of GATA3+ and c-Maf+ T-cells was found, concordant with the pattern of the normal interfollicular compartment.
  • Nodular lymphocyte predominance type of Hodgkin's lymphoma (NLPHL) and progressively transformed germinal centres cases, showed a majority of c-Maf+ T-cells, consistent with the pattern in normal GCs.
  • NLPHL cases uniformly showed c-Maf+/CD57+ T-cell rosettes around the neoplastic cells; these rosettes were absent in "paragranuloma-type" T-cell/histiocyte rich B-cell lymphoma.
  • [MeSH-major] Hodgkin Disease / immunology. T-Lymphocyte Subsets / immunology. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. GABA Plasma Membrane Transport Proteins / metabolism. Germinal Center / immunology. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-maf / metabolism. T-Box Domain Proteins / metabolism. T-Lymphocytes, Helper-Inducer / immunology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1996 Mar;4(3):313-9 [8624821.001]
  • [Cites] Blood. 1996 Jan 15;87(2):465-71 [8555467.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4457-63 [9616139.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):27-33 [9888701.001]
  • [Cites] Immunity. 1999 Jun;10(6):745-51 [10403649.001]
  • [Cites] Semin Hematol. 1999 Jul;36(3):220-32 [10462322.001]
  • [Cites] Semin Hematol. 1999 Jul;36(3):242-52 [10462324.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):127-34 [15632006.001]
  • [Cites] Hum Pathol. 2005 Jan;36(1):10-5 [15712176.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] J Pathol. 2006 Feb;208(3):423-30 [16353293.001]
  • [Cites] Cell. 2000 Mar 17;100(6):655-69 [10761931.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):345-50 [11100882.001]
  • [Cites] J Exp Med. 2002 Apr 15;195(8):1003-12 [11956291.001]
  • [Cites] Br J Haematol. 2002 May;117(2):366-72 [11972519.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S109-20 [11983157.001]
  • [Cites] Nat Immunol. 2002 Jun;3(6):549-57 [12006974.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:44-51 [12078902.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2498-506 [12193719.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4084-9 [12893768.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):292-7 [15323146.001]
  • [Cites] Haematologica. 2004 Aug;89(8):957-64 [15339679.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1149-56 [15448689.001]
  • [Cites] Histopathology. 1979 Jul;3(4):295-308 [468131.001]
  • [Cites] Am J Pathol. 1989 Aug;135(2):351-7 [2675617.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):219-26 [2405631.001]
  • [Cites] Hum Immunol. 1991 May;31(1):67-75 [1715336.001]
  • [Cites] Am J Surg Pathol. 1992 Jan;16(1):37-48 [1728195.001]
  • [Cites] J Virol. 1993 Apr;67(4):2133-41 [8383235.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21597-603 [9261181.001]
  • (PMID = 17158640.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GABA Plasma Membrane Transport Proteins; 0 / MAF protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-maf; 0 / SLC6A11 protein, human; 0 / T-Box Domain Proteins; 0 / T-box transcription factor TBX21; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2014845
  •  go-up   go-down


22. Rahemtullah A, Reichard KK, Preffer FI, Harris NL, Hasserjian RP: A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma. Am J Clin Pathol; 2006 Nov;126(5):805-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma.
  • Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma in which T-cell subsets have not been studied specifically.
  • We reviewed 24 cases of NLPHL and compared flow cytometric results with those of 13 progressively transformed germinal centers (PTGC) cases, 78 nonspecific reactive hyperplasia (RH) cases, and 31 classical Hodgkin lymphoma (CHL) cases.
  • The presence of a CD4+CD8+ T-cell population in NLPHL may reflect an activated or reactive T-cell subset and should not lead to a misdiagnosis of T-cell lymphoma.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / pathology. Hodgkin Disease / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Antigens, CD4 / analysis. Antigens, CD8 / analysis. Biopsy, Fine-Needle. Child. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050078.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, CD4; 0 / Antigens, CD8
  •  go-up   go-down


23. Fu XH, Wang SS, Huang Y, Xiao J, Zhai LZ, Xia ZJ, Huang HQ, Sun XF, Lin TY: [Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma]. Ai Zheng; 2008 Nov;27(11):1197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma].
  • BACKGROUND & OBJECTIVE: Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's Lymphoma (CHL) express B-cell marker CD20 with a reported frequency of 5%-58%.
  • [MeSH-major] Antigens, CD20 / metabolism. Hodgkin Disease / immunology. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antigens, CD15 / metabolism. Antigens, CD30 / metabolism. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000453.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30
  •  go-up   go-down


24. Minami J, Dobashi N, Asai O, Yano S, Osawa H, Takei Y, Yahagi Y, Takahara S, Ogasawara Y, Yamaguchi Y, Kobayashi T, Morikawa N, Nikaido T, Aiba K, Usui N: Two cases of mediastinal gray zone lymphoma. J Clin Exp Hematop; 2010;50(2):143-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of mediastinal gray zone lymphoma.
  • Mediastinal gray zone lymphoma (MGZL) represents a range of tumors possessing characteristics of both nodular sclerosis classical Hodgkin lymphoma (NSHL) and mediastinal large B-cell lymphoma (MLBCL).
  • In patient 2, the tumor was a composite lymphoma with both NSHL and MLBCL components.
  • [MeSH-major] Lymphoma / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Peripheral Blood Stem Cell Transplantation. Radiotherapy. Young Adult

  • Genetic Alliance. consumer health - Gray zone lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123972.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Ambinder RF: Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol; 2005 Oct 20;23(30):7604-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study.
  • PURPOSE: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome.
  • PATIENTS AND METHODS: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human. Hodgkin Disease
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186595.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-65107; United States / NCI NIH HHS / CA / R03 CA-63245; United States / NCI NIH HHS / CA / R29 CA-50381; United States / ODCDC CDC HHS / CC / U55/CCR921930-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 52
  •  go-up   go-down


26. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood; 2008 Jan 1;111(1):109-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
  • Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity.
  • Between 1999 and 2004, the German Hodgkin Study Group (GHSG) investigated the activity of rituximab (375 mg/m(2) in 4 doses) in a phase 2 trial in 21 relapsed or refractory NLPHL patients.
  • The remaining cases were reclassified as Hodgkin lymphoma transformed to T-cell rich B-cell lymphoma (TCRBCL; n = 2) or CD20(+) classical Hodgkin lymphoma (cHL; n = 4).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Germany. Humans. Kaplan-Meier Estimate. Lymphocytes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Male. Middle Aged. Recurrence. Remission Induction. Rituximab. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938252.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


27. Trimeche M, Korbi S, Ziadi S, Amara K, Boniver J, de Leval L: [Molecular characterization of Epstein-Barr virus associated with classical Hodgkin's lymphoma in Tunisia: prevalence of the LMP1 oncogene deletions and A and B viruses strains]. Ann Biol Clin (Paris); 2005 Mar-Apr;63(2):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular characterization of Epstein-Barr virus associated with classical Hodgkin's lymphoma in Tunisia: prevalence of the LMP1 oncogene deletions and A and B viruses strains].
  • [Transliterated title] Caractérisation moléculaire du virus d'Epstein-Barr associé au lymphome de Hodgkin classique en Tunisie: prévalence des délétions de l'oncogène LMP1 et des souches virales A et B.
  • Epstein-Barr virus (EBV) is detected in Hodgkin's lymphoma (HL) at variable frequencies, depending on various factors including the geographic location.
  • [MeSH-major] Herpesvirus 4, Human / genetics. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Child. Child, Preschool. DNA, Viral / analysis. Data Interpretation, Statistical. Female. Gene Deletion. Genotype. Humans. Lymphatic Diseases / virology. Male. Middle Aged. Oncogene Proteins, Viral. Polymerase Chain Reaction. Prevalence. Sex Factors. Tunisia. Viral Matrix Proteins / genetics. Virus Latency / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771977.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Oncogene Proteins, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


28. Krishnamurthy S, Hassan A, Frater JL, Paessler ME, Kreisel FH: Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease. Int J Surg Pathol; 2010 Aug;18(4):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
  • Because of its rarity, pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) are not well understood, and it is unclear whether its biological behavior is more closely related to classical Hodgkin disease or to monomorphic B-cell PTLD.
  • Histologically, all cases of HL-like PTLD resembled classical HL with typical Reed-Sternberg (RS) cells and a cellular background mimicking mixed cellularity subtype.
  • Whereas Epstein-Barr virus early RNA expression is normally restricted to RS cells of classical HL, it was expressed in both RS-like cells and background lymphocytes in HL-like PTLD.
  • [MeSH-major] B-Lymphocytes / pathology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Immunosuppression. Immunosuppressive Agents / adverse effects. Male. Middle Aged. Postoperative Complications. RNA-Binding Proteins / metabolism. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Ribosomal Proteins / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Surg Pathol. 2010 Oct;18(5):444
  • (PMID = 19578050.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunosuppressive Agents; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


29. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, Brousse N, Hermine O: Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One; 2009;4(7):e6341
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.
  • Although most classical Hodgkin lymphoma patients are cured, a significant minority fail after primary therapy and may die as result of their disease.
  • We evaluated 59 patients (18 with primary refractory or early relapse disease and 41 responders) for bcl2, Ki67, CD20, TiA1 and c-kit expression by semi-quantitative immunohistochemical study and correlated the results with the response to treatment.The results showed that expression of bcl2 and CD20 in Hodgkin and Reed Sternberg cells, and expression of TiA1 in micro-environmental lymphocytes, and c-kit positive mast cells in microenvironment, were independent prognostic markers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Pract. 2001 Mar-Apr;9(2):71-80 [11879282.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1278-87 [11870170.001]
  • [Cites] Cell Death Differ. 2002 Jul;9(7):750-7 [12058280.001]
  • [Cites] Br J Haematol. 2002 Jul;118(1):195-201 [12100148.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1370-7 [12196362.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):122-4 [12358914.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1381-6 [12684408.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2320-5 [12805333.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):197-201 [12949794.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):673-9 [13130314.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:225-47 [14633784.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1664-73 [15117989.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):54-9 [15124135.001]
  • [Cites] Br J Haematol. 2004 Jun;125(6):701-8 [15180859.001]
  • [Cites] J Allergy Clin Immunol. 2004 Jul;114(1):13-9; quiz 20 [15241338.001]
  • [Cites] Ups J Med Sci. 2004;109(3):179-228 [15508524.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2118-22 [8481913.001]
  • [Cites] Am J Clin Oncol. 1994 Jun;17(3):185-8 [7514847.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3299-305 [8896393.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3A):1541-9 [9179193.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:79-81 [9209647.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2429-36 [9310494.001]
  • [Cites] Blood. 1998 Apr 15;91(8):3011-6 [9531614.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):376-83 [9578089.001]
  • [Cites] Neoplasma. 1998;45(3):140-7 [9717525.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1522-9 [15632410.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):557-66 [15665852.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3773-9 [15809450.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1301-6 [16109607.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2360-2 [16224482.001]
  • [Cites] Eur J Haematol. 2006 Apr;76(4):278-83 [16519698.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • (PMID = 19623262.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2710003
  •  go-up   go-down


30. Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant; 2007 Jan;39(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
  • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma.
  • We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n=61) or primary refractory (n=6) Hodgkin's lymphoma.
  • In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS.
  • LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115062.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


31. Atayar C, Poppema S, Visser L, van den Berg A: Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol; 2006 Feb;208(3):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts.
  • Little is known about the cytokine profile of nodular lymphocyte predominance Hodgkin's lymphoma (NLPHL) and the significance of the characteristic rosetting CD4(+)/CD57(+) T cells.
  • We analysed the T lymphocyte populations isolated from lymph node suspensions from five patients with NLPHL, two with follicular hyperplasia and progressive transformation of germinal centres (PTGC), three with classical Hodgkin's lymphoma (CHL) and five with hyperplasia of the tonsil.
  • [MeSH-major] Cytokines / genetics. Gene Expression Profiling. Hodgkin Disease / immunology. Oligonucleotide Array Sequence Analysis. Palatine Tonsil / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD57 / immunology. CD4-Positive T-Lymphocytes / immunology. Female. Flow Cytometry. Humans. Hyperplasia. Interferon-gamma / genetics. Interleukin-13 / genetics. Interleukin-2 / genetics. Interleukin-4 / genetics. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353293.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Cytokines; 0 / Interleukin-13; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


32. Diepstra A, Poppema S, Boot M, Visser L, Nolte IM, Niens M, Te Meerman GJ, van den Berg A: HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens; 2008 Mar;71(3):219-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.
  • Classical Hodgkin's lymphoma (cHL) is characterized by the presence of an abundant reactive infiltrate, lacking effective cytotoxic responses.
  • Especially in Epstein-Barr virus (EBV)-negative cHL, the neoplastic Hodgkin-Reed-Sternberg (HRS) cells have lost protein expression of major histocompatibility complex (MHC) class I, enabling escape from cytotoxic T lymphocyte (CTL) responses.
  • [MeSH-major] HLA Antigens / metabolism. Histocompatibility Antigens Class I / metabolism. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Child. Female. Genetic Markers. Genotype. HLA-A Antigens / genetics. HLA-G Antigens. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. Male. Middle Aged. Reed-Sternberg Cells / immunology. Reed-Sternberg Cells / virology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18257895.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / HLA Antigens; 0 / HLA-A Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


33. Bosch Príncep R, Lejeune M, Salvadó Usach MT, Jaén Martínez J, Pons Ferré LE, Alvaro Naranjo T: Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol; 2005 Oct;84(10):661-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
  • This study aimed to assess the differences in the cellular composition of the inflammatory reactive background around tumoral cells of classical Hodgkin's lymphomas (cHL) inside and outside the HIV settings.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / metabolism. HIV. HIV Infections / metabolism. Hodgkin Disease / metabolism. Serine Endopeptidases / metabolism
  • [MeSH-minor] Adult. CD4-CD8 Ratio / methods. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD4-Positive T-Lymphocytes / virology. Female. Granzymes. Humans. Inflammation / metabolism. Inflammation / pathology. Inflammation / virology. Male. Middle Aged. Poly(A)-Binding Proteins. RNA-Binding Proteins / metabolism. Retrospective Studies


34. Kelley TW, Pohlman B, Elson P, Hsi ED: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol; 2007 Dec;128(6):958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
  • We studied the prognostic importance of tumor-infiltrating regulatory T lymphocytes (Tregs) and cytotoxic T/NK lymphocytes (CTLs) in 98 diagnostic biopsy specimens from patients with classical Hodgkin lymphoma (cHL).
  • [MeSH-major] Forkhead Transcription Factors / metabolism. Granzymes / metabolism. Hodgkin Disease / immunology. Killer Cells, Natural / immunology. Membrane Transport Proteins / metabolism. Myelin Proteins / metabolism. Proteolipids / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Lymphocytes, Tumor-Infiltrating / immunology. Male. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Retrospective Studies. Survival Rate. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024321.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.21.- / Granzymes
  •  go-up   go-down


35. Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA: Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol Cell Biochem; 2009 Jan;321(1-2):95-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma.
  • Hodgkin and Reed-Sternberg (H-RS) cells of classical Hodgkin lymphoma (cHL) present an impaired expression of immunoglobulin genes, but escape apoptotic death.
  • [MeSH-major] Apoptosis / immunology. Hodgkin Disease / immunology. Isoenzymes / metabolism. Nitric Oxide Synthase / metabolism. Reed-Sternberg Cells / enzymology. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Dec 30;79(7):1137-46 [7528106.001]
  • [Cites] Histopathology. 1995 Jun;26(6):547-53 [7665145.001]
  • [Cites] Nat Med. 1997 Jun;3(6):614-20 [9176486.001]
  • [Cites] Free Radic Biol Med. 1998 Sep;25(4-5):434-56 [9741580.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] Histopathology. 2001 Aug;39(2):172-8 [11493334.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Cell Res. 2002 Dec;12(5-6):311-20 [12528889.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Trends Biochem Sci. 1997 Dec;22(12):477-81 [9433128.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2429-36 [9310494.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):255-66 [15464038.001]
  • [Cites] Eur J Pharmacol. 1998 Jun 26;351(3):261-72 [9721017.001]
  • [Cites] Hypertension. 1994 Jun;23(6 Pt 2):1121-31 [7515853.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2443-51 [9516144.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3935-41 [12433696.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):483-8 [12688319.001]
  • [Cites] Pathol Int. 2002 Sep;52(9):578-85 [12406187.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1270-4 [8238244.001]
  • [Cites] Int Immunopharmacol. 2001 Aug;1(8):1421-41 [11515809.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Surgery. 2002 Jul;132(1):20-6 [12110791.001]
  • [Cites] Pharmacol Rev. 1991 Jun;43(2):109-42 [1852778.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):488-93 [11839668.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):60-6 [11668479.001]
  • [Cites] J Pathol. 1997 Jul;182(3):307-10 [9349233.001]
  • [Cites] Mol Cell Biochem. 2006 Oct;290(1-2):205-9 [16924421.001]
  • [Cites] Ann Hematol. 2001 Jan;80(1):2-8 [11233771.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Histopathology. 2001 Aug;39(2):179-86 [11493335.001]
  • [Cites] Am J Clin Pathol. 1996 Dec;106(6):728-38 [8980348.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1301-6 [16109607.001]
  • [Cites] Histopathology. 2004 Mar;44(3):257-67 [14987230.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2442-7 [8637893.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8823-8 [9671763.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):376-83 [9578089.001]
  • [Cites] Blood. 2001 May 15;97(10):3191-6 [11342448.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31437-41 [9813055.001]
  • (PMID = 18830569.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


36. Decaudin D, Marszak FB, Couturier J, Mathiot C, Martin A, Némati F, Lantz O, Santo Jd, Arnaud P, Bordier V, Vincent-Salomon A, Poupon MF: High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice. Anticancer Drugs; 2006 Jul;17(6):685-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
  • The objectives were to characterize an Epstein-Barr virus-associated human B-cell lymphoma obtained from Hodgkin's xenograft, and to evaluate the in-vivo combination of rituximab and/or gemcitabine.
  • A lymph node biopsy sample from a patient with Hodgkin's disease was xenografted into Rag gamma(c)(-/-) mice.
  • Histologic features of the patient's biopsy concluded on classical CD15/CD30-positive Hodgkin's disease without expression of Epstein-Barr virus proteins.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / pathogenicity. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Biopsy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / physiology. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / metabolism. Lymph Nodes / pathology. Lymph Nodes / transplantation. Lymph Nodes / virology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Mice. Mice, Knockout. Mice, SCID. Nucleic Acid Hybridization. Rituximab. Sialic Acid Binding Ig-like Lectin 2 / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917214.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Homeodomain Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Sialic Acid Binding Ig-like Lectin 2; 0W860991D6 / Deoxycytidine; 128559-51-3 / RAG-1 protein; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


37. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerri L: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood; 2009 Mar 19;113(12):2765-3775
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
  • The outcome of classical Hodgkin lymphoma (cHL) patients may be related to the tumor microenvironment, which in turn may be influenced by Epstein-Barr virus (EBV) infection.
  • Their gene expression profile differed from that of histiocyte T cell-rich B-cell lymphoma (H/TCRBCL) samples that were used as controls, mainly due to high expression of PDCD1/PD-1 in H/TCRBCL.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. Prognosis. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Reed-Sternberg Cells / virology. Remission Induction. Stromal Cells / metabolism. Stromal Cells / pathology. Survival Analysis. T-Lymphocyte Subsets / chemistry. T-Lymphocyte Subsets / immunology. Th1 Cells / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096012.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE13996
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


38. Schain F, Schain D, Mahshid Y, Liu C, Porwit A, Xu D, Claesson HE, Sundström C, Björkholm M, Sjöberg J: Differential expression of cysteinyl leukotriene receptor 1 and 15-lipoxygenase-1 in non-Hodgkin lymphomas. Clin Lymphoma Myeloma; 2008 Dec;8(6):340-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of cysteinyl leukotriene receptor 1 and 15-lipoxygenase-1 in non-Hodgkin lymphomas.
  • We have recently reported that the cysteinyl leukotriene receptor 1 (CysLT1) and 15-lipoxygenase-1 (15-LO-1) are expressed by the malignant Hodgkin Reed-Sternberg cells of Hodgkin lymphoma and certain Hodgkin lymphoma cell lines, and that these cells convert arachidonic acid to the novel proinflammatory eoxins.
  • MATERIALS AND METHODS: The expression of the CysLT1 receptor and 15-LO-1 was investigated in a broad range of non-Hodgkin lymphomas (NHLs) by immunohistochemistry.
  • The functionality of the CysLT1 receptor in primary mediastinal B-cell lymphoma (PMBCL) cell lines was studied by calcium mobilization assays.
  • RESULTS: Primary mediastinal B-cell lymphoma was the only NHL entity showing tumor cells positive for the CysLT1 receptor (9 of 10 tumors), and the PMBCL cell line Med-B1 expressed functional CysLT1 receptors, responding with a robust calcium signal upon cysteinyl leukotriene challenge.
  • Thus, this further corroborates the pathologic overlap between PMBCL and classical Hodgkin lymphoma.
  • [MeSH-major] Arachidonate 15-Lipoxygenase / metabolism. Lymphoma, Non-Hodgkin / metabolism. Receptors, Leukotriene / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Calcium / metabolism. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression. Humans. Immunohistochemistry. Leukotriene D4 / pharmacology. Male. Middle Aged

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064398.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Leukotriene; 0 / leukotriene D4 receptor; 73836-78-9 / Leukotriene D4; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; SY7Q814VUP / Calcium
  •  go-up   go-down


39. Hua MT, Blaise P, De Leval L, Rakic JM: Frosted branch angiitis with undiagnosed Hodgkin lymphoma. Eur J Ophthalmol; 2009 Mar-Apr;19(2):310-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frosted branch angiitis with undiagnosed Hodgkin lymphoma.
  • PURPOSE: To report the case of a patient with bilateral frosted branch angiitis and undiagnosed Hodgkin lymphoma.
  • A supraclavicular lymph node biopsy led to the diagnosis of nodular sclerosis Hodgkin lymphoma.
  • CONCLUSIONS: The occurrence of frosted branch angiitis in combination with classical Hodgkin lymphoma, although possibly coincidental, raises the possibility of a paraneoplastic syndrome.
  • Thus, we suggest that, for patients with frosted branch angiitis, Hodgkin lymphoma should be considered in the diagnostic workup.
  • [MeSH-major] Hodgkin Disease / diagnosis. Retinal Vasculitis / diagnosis
  • [MeSH-minor] Administration, Oral. Biopsy. Fluorescein Angiography. Glucocorticoids / therapeutic use. Humans. Infusions, Intravenous. Lymph Nodes / pathology. Male. Methylprednisolone / therapeutic use. Visual Acuity. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253256.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


40. Martini M, Hohaus S, Petrucci G, Cenci T, Pierconti F, Massini G, Teofili L, Leone G, Larocca LM: Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. Am J Clin Pathol; 2008 Mar;129(3):472-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.
  • An important pathogenetic mechanism in Hodgkin lymphoma (HL) is the interaction between the neoplastic and reactive cells mediated by a complex network of cytokines with activation of cytokine signal transduction (STAT) pathways.
  • The detection of pSTAT5 in Hodgkin and Reed-Sternberg (HRS) cells in classical HL (cHL) was not associated with any clinical and biologic features evaluated, including Epstein-Barr virus status.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. STAT5 Transcription Factor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epstein-Barr Virus Infections. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Phosphorylation. Prognosis. Radiotherapy. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285272.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT5 Transcription Factor
  •  go-up   go-down


41. Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Assis MG, Eiras DP, Dobo C, Oliveira JS: Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil. Hematol Oncol; 2010 Sep;28(3):137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil.
  • INTRODUCTION: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein-Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20128016.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Muenst S, Hoeller S, Dirnhofer S, Tzankov A: Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol; 2009 Dec;40(12):1715-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
  • The distribution of PD-1+ lymphocytes in the microenvironment of Hodgkin lymphoma is not random and can serve as a diagnostic marker.
  • We measured the number of PD-1+ lymphocytes in Hodgkin lymphoma and correlated it with the remaining background lymphocyte populations and known biological and clinical key data on a tissue microarray platform encompassing 280 cases of classical Hodgkin lymphoma and 3 cases of nodular lymphocyte-predominant Hodgkin lymphoma.
  • The number of PD-1+ tumor-infiltrating lymphocytes in 189 evaluable cases was median of 27 and mean of 269 cells/mm(2), being higher in lymphocyte-rich classical Hodgkin lymphoma and lower in the mixed cellularity variant.
  • Rimming of tumor cells by PD-1+ cells was observed in all cases of nodular lymphocyte-predominant Hodgkin lymphoma but only in 1% of classical Hodgkin lymphomas, particularly in lymphocyte-rich and -mixed cellularity variants.
  • Thus, the presence of PD-1+ rosettes around neoplastic cells is typical but not exclusive for nodular lymphocyte-predominant Hodgkin lymphoma because it may be encountered in classical Hodgkin lymphoma.
  • The PD-1+ cell amount was lower in classical Hodgkin lymphoma cases with 9p24 gains (PD-1 ligand 2 locus) and in cases with higher numbers of FOXP3+ regulatory T cells.
  • Along with the latter, PD-1+ cells might represent important lymphoma/host microenvironment modulators.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers, Tumor / immunology. Hodgkin Disease / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Area Under Curve. Female. Forkhead Transcription Factors / biosynthesis. Forkhead Transcription Factors / immunology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Programmed Cell Death 1 Receptor. ROC Curve. T-Lymphocytes, Regulatory / immunology. T-Lymphocytes, Regulatory / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695683.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


43. Israel R, Dorer R, Aboulafia DM: Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy. Am J Med Sci; 2010 Feb;339(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy.
  • As the incidence of human immunodeficiency virus (HIV) infection in women of child bearing age continues to increase in the era of highly active antiretroviral therapy and Hodgkin lymphoma (HL) is the most common non-acquired immunodeficiency syndrome defining malignancy, we anticipate that the number of cases of HIV-associated HL in pregnant women will increase in the near future.
  • Subsequent histopathology and radiographic findings revealed clinical stage IIIA Classical HL.
  • [MeSH-major] HIV Infections / complications. Hodgkin Disease / complications. Pregnancy
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Viral Load


44. Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, Tamaki Y, Matsumoto M, Hirabayashi K, Igarishi S, Masawa N, Nakamura S: Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol; 2006 Jan;14(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases.
  • We conducted clinicopathologic and immunohistochemical analyses of the prevalence of Epstein-Barr virus (EBV) among 24 patients with malignant lymphoma complicating systemic rheumatic diseases. (SRD) These 24 patients included 17 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 2 with systemic sclerosis (SS), and 2 with dermatomyositis (DM).
  • The use of immunosuppressive drugs before the onset of malignant lymphoma was recorded in 15 patients.
  • Histologic and immunohistochemical studies demonstrated that 18 cases (75%) were B-cell lymphoma (RA=12, SLE=2, SS=2, DM=2), 3 (12.5%) were peripheral T-cell lymphoma (RA=3), and 3 (12.5%) were classical Hodgkin lymphoma (RA=2, SLE=1).
  • As in previous reports, there was an increased frequency of diffuse large B-cell lymphoma (50%) in the present series.
  • EBV-encoded small RNAs (Epstein-Barr early region [EBER]-) and/or LMP-1+tumor cells were identified in only 3 cases of classical Hodgkin lymphomas.
  • Our findings suggested EBV-associated lymphoma comprised only a small fraction of all non-Hodgkin's lymphomas in the general SRD patient population.
  • [MeSH-major] Lymphoma / complications. Rheumatic Diseases / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / pathology. Dermatomyositis / complications. Dermatomyositis / pathology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / epidemiology. Epstein-Barr Virus Infections / pathology. Female. Herpesvirus 4, Human / genetics. Hodgkin Disease / complications. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Japan. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. RNA, Viral / analysis. Scleroderma, Systemic / complications. Scleroderma, Systemic / pathology


45. Salama ME, Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL: The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. Int J Surg Pathol; 2010 Apr;18(2):121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma.
  • Mediastinal diffuse large B-cell lymphoma (Med-DLBCL) is a subtype of DLBCL that has morphologic and clinical similarities and phenotypic overlaps with classical Hodgkin lymphoma (CHL) involving the mediastinum.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Receptors, IgE / metabolism. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reed-Sternberg Cells / pathology. Retrospective Studies. Young Adult


46. Mader A, Bruderlein S, Wegener S, Melzner I, Popov S, Muller-Hermelink HK, Barth TF, Viardot A, Moller P: U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res; 2007;119(3-4):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma.
  • The Hodgkin cell line U-HO1 was established from a malignant pleural effusion of a 23-year-old male patient during the end stage of refractory nodular sclerosing classical Hodgkin lymphoma (cHL).
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Cell Line. Chromosome Banding. Chromosomes, Human, Pair 2. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Polymerase Chain Reaction. RNA Precursors / genetics


47. Niitsu N, Nakamine H, Okamoto M, Tamaru JI, Hirano M: A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Ann Oncol; 2008 Nov;19(11):1941-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma.
  • BACKGROUND: We carried out immunohistochemistry to examine the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in patients with classical Hodgkin's lymphoma (CHL).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647967.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


48. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma; 2007 Jul;48(7):1313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
  • Constitutive activation of nuclear factor-kappaB (NF-kappaB) has been described in patient-derived Reed - Sternberg cells and Hodgkin lymphoma (HL) cell lines and contributes to the proliferation and survival of HL.
  • To evaluate this hypothesis, the Cancer and Leukemia Group B (CALGB) conducted a multi-institutional phase II trial of single agent bortezomib in patients with relapsed or refractory classical HL.
  • Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL.
  • [MeSH-major] Boronic Acids / administration & dosage. Hodgkin Disease / drug therapy. Pyrazines / administration & dosage. Salvage Therapy / methods
  • [MeSH-minor] Adult. Bortezomib. Disease Progression. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613759.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / K23 CA109004-01A1
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


49. Younes A, Wong F: Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Ann Oncol; 2009 Jun;20(6):1147-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465429.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


50. Jegalian AG, Facchetti F, Jaffe ES: Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol; 2009 Nov;16(6):392-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normally found in small quantities in primary and secondary lymphoid organs, PDCs accumulate in a variety of inflammatory conditions, including Kikuchi-Fujimoto lymphadenopathy, hyaline-vascular Castleman disease, and autoimmune diseases, and in certain malignancies such as classical Hodgkin lymphoma and carcinomas.
  • Formerly called blastic natural killer cell lymphoma or CD4/CD56 hematodermic neoplasm, BPDCN, unlike natural killer cell lymphomas, is not associated with Epstein-Barr virus infection and is generally not curable with treatment regimens for non-Hodgkin lymphomas.
  • In fact, this entity is no longer considered to be a lymphoma and instead represents a unique precursor hematopoietic neoplasm.
  • Acute leukemia therapy regimens may lead to sustained clinical remission of BPDCN, with bone marrow transplantation in first complete remission potentially curative in adult patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Lineage. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Male. Toll-Like Receptors / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851130.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  • [Number-of-references] 151
  •  go-up   go-down


51. Aldred V, Vassallo J, Froes M Campos AH, Augusto Soares F: CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients. Leuk Lymphoma; 2008 Nov;49(11):2198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients.
  • [MeSH-major] Antigens, CD20 / analysis. Hodgkin Disease / mortality. Hodgkin Disease / pathology. Reed-Sternberg Cells / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Child, Preschool. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18661400.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • Three years and eight months after CBSCT, the enlarged cervical lymph node was histologically diagnosed as EBV associated post-transplant HL, which showed immunophenotypes of classical HL and latency type II EBV infection.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


53. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A, German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol; 2008 Jan 20;26(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
  • PURPOSE: Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is rare and differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • To shed more light on the prognosis and outcome of LPHL, we reviewed all LPHL patients registered in the German Hodgkin Study Group (GHSG) database, comparing patient characteristics and treatment outcome with cHL patients.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):368-9 [18542117.001]
  • (PMID = 18086799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G: Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol; 2006 Nov;77(5):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
  • OBJECTIVES: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens.
  • [MeSH-major] Antigens, CD30 / blood. Biomarkers, Tumor / blood. Hodgkin Disease / blood. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Failure. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879607.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


55. Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, Ambinder RF, Zheng T, Mueller NE: Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):976-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.
  • We found that regular use of aspirin may reduce the risk of Hodgkin lymphoma (HL), a common cancer of adolescents and young adults in the United States.
  • Twenty single nucleotide polymorphisms (SNP) in seven genes were genotyped in DNA from 473 classical HL cases and 373 controls enrolled between 1997 and 2000 in a population-based case-control study in the Boston, Massachusetts, metropolitan area and the state of Connecticut.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858047 for PMID:19223558 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):354-8 [10453811.001]
  • [Cites] J Biol Chem. 1999 Sep 17;274(38):27307-14 [10480951.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Genet Epidemiol. 2005 Apr;28(3):261-72 [15637718.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):646-51 [15858823.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6400-8 [16155026.001]
  • [Cites] Int J Immunogenet. 2005 Dec;32(6):401-5 [16313306.001]
  • [Cites] N Engl J Med. 2006 Jan 26;354(4):421-2 [16436780.001]
  • [Cites] Exp Hematol. 2006 Apr;34(4):399-406 [16569586.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):785-97 [16528384.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):890-6 [16818852.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Am J Epidemiol. 2006 Oct 15;164(8):794-804 [16923772.001]
  • [Cites] Cancer Lett. 2006 Nov 8;243(1):47-54 [16387424.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):92-9 [16540234.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):859-66 [17492467.001]
  • [Cites] Scand J Gastroenterol. 2007 Nov;42(11):1332-8 [17852842.001]
  • [Cites] Immunogenetics. 1999 Dec;50(5-6):363-5 [10630303.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1151-8 [10904088.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):647-53 [10982757.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):297-310 [11301346.001]
  • [Cites] Science. 2001 Aug 24;293(5534):1495-9 [11520989.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45225-35 [11571291.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):259-67 [11863222.001]
  • [Cites] Genes Immun. 2002 Jun;3(4):211-9 [12058256.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):43-8 [12377412.001]
  • [Cites] Genes Immun. 2003 Sep;4(6):450-4 [12944982.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Hum Mol Genet. 2004 Jan 1;13(1):35-45 [14613970.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):153-6 [13680285.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):305-15 [14970279.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):72-9 [15102433.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • (PMID = 19223558.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09001-24; United States / NCI NIH HHS / CA / CA130048-01; United States / NCI NIH HHS / CA / K07 CA115687; United States / NCI NIH HHS / CA / R03 CA130048-01; United States / NCI NIH HHS / CA / R03 CA130048; United States / NCI NIH HHS / CA / P01 CA069266; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / P01 CA069266-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B
  • [Other-IDs] NLM/ NIHMS97295; NLM/ PMC2720066
  •  go-up   go-down


56. Leenman EE, Mukhina MS, Girshovich MM, Kanaev SV, Konoplev SN, Pozharisskiĭ KM: [The place of dendritic cells in the microenviroment in Hodgkin's lymphoma]. Arkh Patol; 2010 Mar-Apr;72(2):3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The place of dendritic cells in the microenviroment in Hodgkin's lymphoma].
  • Dendritic cells (DCs) are the least studied microenvironment elements in Hodgkin's lymphoma (HL).
  • Ninety-five lymph nodes were morphologically and immunohistochemically studied in patients with classical HL.
  • [MeSH-major] Dendritic Cells. Dendritic Cells, Follicular. Hodgkin Disease. Lymph Nodes. Reed-Sternberg Cells
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / immunology. Antigens, CD1 / immunology. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Female. Humans. Immunohistochemistry / methods. Lectins, C-Type / immunology. Male. Mannose-Binding Lectins / immunology. Middle Aged. Receptors, IgE / immunology. Retrospective Studies. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698307.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / CD1a antigen; 0 / CD207 protein, human; 0 / Lectins, C-Type; 0 / Mannose-Binding Lectins; 0 / Receptors, IgE
  •  go-up   go-down


57. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • IF-RT seems to be emerging as a treatment of choice for patients with stage IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer, have adopted IF-RT as the treatment of choice for these patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


58. Schain F, Tryselius Y, Sjöberg J, Porwit A, Backman L, Malec M, Xu D, Vockerodt M, Baumforth KR, Wei W, Murray PG, Björkholm M, Claesson HE: Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma. Int J Cancer; 2008 Nov 15;123(10):2285-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma.
  • Classical Hodgkin lymphoma (cHL) is characterized histologically by a minority of malignant Hodgkin Reed-Sternberg cells surrounded by abundant inflammatory cells, generally believed to be of major importance in the pathophysiology of the disease.
  • Immunohistochemical studies of cHL biopsies and microarray analysis of microdissected cells revealed that the CysLT(1) receptor is expressed also by primary Hodgkin Reed-Sternberg cells.
  • As these cells are surrounded by CysLT-producing eosinophils, macrophages and mast cells, our results suggest the CysLTs as mediators in the pathogenesis of cHL, contributing to the aberrant cytokine network of this lymphoma.
  • [MeSH-major] Cysteine / chemistry. Hodgkin Disease / physiopathology. Leukotrienes / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Calcium Signaling. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Leukotriene D4 / pharmacology. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Receptors, Leukotriene / genetics. Receptors, Leukotriene / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYSTEINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18704935.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leukotrienes; 0 / Receptors, Leukotriene; 0 / cysteinyl leukotriene receptor 2; 0 / leukotriene D4 receptor; 73836-78-9 / Leukotriene D4; K848JZ4886 / Cysteine
  •  go-up   go-down


59. Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O: Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int; 2006 Jun;69(12):2251-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature.
  • Minimal change nephrotic syndrome (MCNS) is described as a paraneoplastic manifestation of classical Hodgkin's lymphoma (cHL).
  • A retrospective study was performed to evaluate a cohort of adult patients who developed MCNS and cHL.
  • MCNS appeared before the diagnosis of lymphoma in eight patients (38.1%) and in this case, it was characterized by a nephrotic syndrome (NS) frequently resistant (50%) or dependent (12.5%) to steroid treatment.
  • In conclusion, MCNS associated with cHL is frequently dependent or resistant to steroid regimen, but remission of NS is obtained with the cure of lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Nephrosis, Lipoid / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Comorbidity. Cytokines / physiology. Female. Humans. Male. Middle Aged. NF-kappa B / physiology. Retrospective Studies. Risk Factors. T-Lymphocytes / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672913.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / NF-kappa B
  • [Number-of-references] 45
  •  go-up   go-down


60. Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, Siebert R, Hay RT, Jarrett RF: Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer; 2009 Sep 15;125(6):1334-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.
  • A consistent feature of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is the constitutive activation of NF-kappaB transcription factors.
  • [MeSH-major] DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / genetics. Herpesvirus 4, Human / physiology. Hodgkin Disease / genetics. I-kappa B Proteins / genetics. Mutation / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Comparative Genomic Hybridization. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19507254.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


61. Martín-Subero JI, Klapper W, Sotnikova A, Callet-Bauchu E, Harder L, Bastard C, Schmitz R, Grohmann S, Höppner J, Riemke J, Barth TF, Berger F, Bernd HW, Claviez A, Gesk S, Frank GA, Kaplanskaya IB, Möller P, Parwaresch RM, Rüdiger T, Stein H, Küppers R, Hansmann ML, Siebert R, Deutsche Krebshilfe Network Project Molecular Mechanisms in Malignant Lymphomas: Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res; 2006 Nov 1;66(21):10332-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
  • However, despite the predominant B-cell origin of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL), the presence of chromosomal translocations in IG loci has not yet been systematically explored.
  • [MeSH-major] Chromosome Breakage. Genes, Immunoglobulin Heavy Chain. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Caspases / genetics. DNA-Binding Proteins / genetics. Female. Genes, myc. Humans. Immunoglobulin Class Switching. Immunoglobulin Constant Regions / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079453.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Constant Regions; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


62. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


63. Benharroch D, Einav I, Feldman A, Levy A, Ariad S, Gopas J: Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited. APMIS; 2010 May;118(5):339-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited.
  • We scrutinized the role of apoptosis of the Hodgkin-Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) and critically reviewed its features in the light of conflicting evidence.
  • These findings support our contention that the role of apoptosis in the HRS cells of Hodgkin lymphoma has not been completely elucidated and is at variance with that in the consensus.
  • [MeSH-major] Apoptosis / physiology. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Herpesvirus 4, Human / metabolism. Herpesvirus 4, Human / pathogenicity. Humans. Immunohistochemistry. Male. Middle Aged. NF-kappa B / metabolism. Viral Matrix Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477808.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  • [Number-of-references] 29
  •  go-up   go-down


64. Bakshi NA, Finn WG, Schnitzer B, Valdez R, Ross CW: Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. Arch Pathol Lab Med; 2007 May;131(5):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
  • Fascin is a sensitive marker for classical Reed-Sternberg cells and has a high negative predictive value for diagnosis of classical Hodgkin lymphoma (CHL).
  • Fascin has been used to distinguish CHL from non-Hodgkin lymphoma.
  • Recently, it was shown that fascin might not help differentiate CHL from anaplastic large cell lymphoma (ALCL).
  • OBJECTIVE: To analyze fascin expression in diffuse large B-cell lymphoma (DLBCL) and also reexamine its usefulness in discriminating CHL from ALCL.
  • Fascin expression was compared across each type of lymphoma with additional correlation between fascin positivity and ALK-1 expression in ALCL performed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carrier Proteins / biosynthesis. Hodgkin Disease / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Microfilament Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity


65. Younes A, Pro B, Fayad L: Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood; 2006 Feb 15;107(4):1731-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Hodgkin Disease / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Bortezomib. Disease Progression. Female. Humans. Male. Middle Aged. Recurrence. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461762.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


66. Falchi L, Capello D, Palumbo B, Rauco A, Emili R, Cianciulli M, Pace R, Capparella V, Liberati F, Liberati AM: A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol; 2007 Nov;79(5):455-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
  • We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin's Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular (PC-HV) form of Castleman's disease (CD).
  • The CD30- and CD15-positive, Reed-Sternberg/Hodgkin cells, only occasionally expressed the CD20 molecule, but not leukocyte common antigen and latent membrane protein-1.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Hyalin / metabolism. Immunologic Factors / therapeutic use. Plasma Cells
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Female. Fluorodeoxyglucose F18. Humans. Positron-Emission Tomography. Radiopharmaceuticals. Radiotherapy, Adjuvant. Recurrence. Rituximab. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Jun 13;17(9):1409-10 [12799570.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):585-6 [15090823.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1939-41 [15223659.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2413-8 [1710152.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):602-5 [8302342.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):569-71 [8652374.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] J Pathol. 1997 Sep;183(1):44-50 [9370946.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):482-5 [10086783.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):302-5 [15795923.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):119-23 [16405432.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):882-8 [10843293.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):1-5 [11815953.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • (PMID = 17908180.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2121125
  •  go-up   go-down


67. Casaccia M, Torelli P, Cavaliere D, Santori G, Panaro F, Valente U: Minimal-access splenectomy: a viable alternative to laparoscopic splenectomy in massive splenomegaly. JSLS; 2005 Oct-Dec;9(4):411-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for splenectomy were non-Hodgkin's lymphoma in 5 cases and idiopathic myelofibrosis in 4.
  • It combines the advantages of hand assistance like shorter operative times and increased safety of the procedure to the classical benefits of minimally invasive surgery.

  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 1999 Dec;13(12):1220-5 [10594270.001]
  • [Cites] Surg Endosc. 1999 Sep;13(9):865-8 [10449840.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):965-71 [12163965.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):235-40 [12894017.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):720-3 [3756435.001]
  • [Cites] J Clin Ultrasound. 1990 Sep;18(7):569-74 [2170456.001]
  • [Cites] Am Surg. 1991 Feb;57(2):108-13 [1992865.001]
  • [Cites] Presse Med. 1991 Dec 21-28;20(44):2263 [1838167.001]
  • [Cites] Surg Endosc. 1992 Jul-Aug;6(4):183-5 [1387735.001]
  • [Cites] Can J Surg. 1995 Feb;38(1):69-72 [7882213.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):290-6 [8604910.001]
  • [Cites] World J Surg. 1996 Nov-Dec;20(9):1156-9 [8864075.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):108-12 [9069137.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(2):79-82 [9128872.001]
  • [Cites] Arch Surg. 1997 Jun;132(6):642-6 [9197857.001]
  • [Cites] Surg Endosc. 1998 Jan;12(1):73-5 [9419310.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):35-9 [9671064.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):192-6 [11918887.001]
  • (PMID = 16381356.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015627
  •  go-up   go-down


68. Gualco G, Weiss LM, Bacchi CE: Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum Pathol; 2008 Oct;39(10):1505-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.
  • In malignant hematological disease, p63 expression has been reported in 22% of follicular lymphoma, about 35% of diffuse large B-cell lymphoma, 23% of chronic lymphocytic leukemia, and in some cases of blast crisis of chronic myelogenous leukemia.
  • Anaplastic large cell lymphoma is a rare disease that accounts for less than 5% of all cases of non-Hodgkin's lymphoma.
  • There is little information concerning p63 expression in this specific type of lymphoma.
  • In some cases, the morphological and phenotypic features between anaplastic large cell lymphoma and classical Hodgkin's lymphoma are similar, making this differential diagnosis challenging.
  • We studied p63 expression using a tissue microarray approach in 154 cases of anaplastic large cell lymphoma, including 38% anaplastic large cell kinase positive and 62% anaplastic large cell kinase negative, and 58 Hodgkin's lymphoma cases.
  • Sixty-eight cases of anaplastic large cell lymphoma (44%) showed p63 nuclear positivity (41% of anaplastic large cell kinase positive and 47% of anaplastic large cell kinase negative).
  • Of 130 cases of systemic-anaplastic large cell lymphoma, 42% showed p63 positivity.
  • The neoplastic cells expressed p63 in 38% of the cases of CD45-negative/anaplastic large cell kinase-negative null cell-type anaplastic large cell lymphoma, a subgroup that offers the most difficulties in the differential diagnosis with classical Hodgkin's lymphoma.
  • In contrast, none of the cases of classical Hodgkin's lymphoma demonstrated any p63 expression.
  • These results demonstrate that p63 protein expression is frequently expressed in a subset of anaplastic large cell lymphoma cases and may be used as a potential tool in the differential diagnosis between anaplastic large cell lymphoma and classical Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):709-17 [15151211.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1199-206 [12368193.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):199-204 [12579989.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):223-9 [16434897.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] Urology. 2004 Jun;63(6):1079-83 [15183954.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Pathol Biol (Paris). 1997 Dec;45(10):898-908 [9769955.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42 [16082248.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):752-8 [16224147.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):233-9 [17297297.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Arch Pathol Lab Med. 2007 May;131(5):742-7 [17488159.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7113-21 [14612504.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • (PMID = 18620733.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS127050; NLM/ PMC2744879
  •  go-up   go-down


69. Cheuk W, Tam FK, Chan AN, Luk IS, Yuen AP, Chan WK, Hung TC, Chan JK: Idiopathic cervical fibrosis--a new member of IgG4-related sclerosing diseases: report of 4 cases, 1 complicated by composite lymphoma. Am J Surg Pathol; 2010 Nov;34(11):1678-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic cervical fibrosis--a new member of IgG4-related sclerosing diseases: report of 4 cases, 1 complicated by composite lymphoma.
  • In the soft tissue lesion of 1 patient, there were expansile foci comprising dense sheets of plasma cells and small lymphoid cells that exhibited κ light chain restriction and clonal immunoglobulin gene rearrangement, consistent with supervening extranodal marginal zone lymphoma.
  • The adjacent lymph node from the same patient showed Epstein-Barr virus (EBV)-positive classical Hodgkin lymphoma with typical morphology and immunophenotype (CD30, CD15, PAX5).
  • Thus lymphoma can supervene in the chronic inflammatory background similar to that recently documented for IgG4-related sclerosing disease of the ocular adnexa.
  • [MeSH-major] Hodgkin Disease / immunology. Immune System Diseases / immunology. Immunoglobulin G / immunology. Inflammation / immunology. Neck / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Fibrosis. Herpesvirus 4, Human / isolation & purification. Humans. Immunophenotyping. Lymph Nodes / immunology. Lymphatic Diseases / immunology. Lymphocytes / immunology. Male. Middle Aged. Plasma Cells / immunology. Sclerosis. Sialadenitis / immunology. Steroids / therapeutic use. Submandibular Gland / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871392.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Steroids
  •  go-up   go-down


70. Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PR, White J, Jarrett RF: Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol; 2005 Feb;128(4):493-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma.
  • The risk of developing Hodgkin's lymphoma (HL) in young adults decreases with an increasing number of C alleles at this position.
  • Although the risk of classical HL in young adults decreased with increasing C alleles, case-control differences were not significant.
  • [MeSH-major] Hodgkin Disease / genetics. Interleukin-6 / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Case-Control Studies. DNA, Neoplasm / genetics. Epstein-Barr Virus Infections / complications. Female. Genotype. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686457.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6
  •  go-up   go-down


71. Unal A, Sari I, Deniz K, Ozkan M, Kontas O, Eser B, Cetin M: Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma; 2005 Nov;46(11):1613-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare tumor type distinct from classical Hodgkin lymphoma and its familial form is unusual.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Family Health. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisolone / therapeutic use. Remission Induction / methods. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236615.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


72. Quiñones-Avila Mdel P, Gonzalez-Longoria AA, Admirand JH, Medeiros LJ: Hodgkin lymphoma involving Waldeyer ring: a clinicopathologic study of 22 cases. Am J Clin Pathol; 2005 May;123(5):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma involving Waldeyer ring: a clinicopathologic study of 22 cases.
  • We report 22 cases of Hodgkin lymphoma involving Waldeyer ring seen at our institution during a 31-year interval.
  • The 3 patients (14%) whose disease was unstaged had concurrent or a history of non-Hodgkin lymphoma.
  • Histologically, the neoplasms were classified as follows: lymphocyte-rich classical, 8 (36%); nodular sclerosis, 7 (32%); mixed cellularity, 4 (18%); unclassified, 2 (9%); and lymphocyte depletion, 1 (5%).
  • Of 7 stage I cases, 4 (57%) were the lymphocyte-rich classical type.
  • Reed-Sternberg and Hodgkin cells were positive for CD15 and CD30 in 20 cases assessed.
  • We conclude that Hodgkin lymphoma rarely involves Waldeyer ring, with the lymphocyte-rich classical type being common at this location.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Hodgkin Disease / pathology. Lymphoid Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Neoplasm Staging. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Reed-Sternberg Cells / virology. Viral Matrix Proteins / metabolism


73. Wang SA, Rahemtullah A, Faquin WC, Roepke J, Harris NL, Hasserjian RP: Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol; 2005 Dec;18(12):1577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature.
  • Hodgkin's lymphoma rarely involves the thyroid gland.
  • We report the clinical and pathologic features of five cases of Hodgkin's lymphoma that presented as thyroid lesions.
  • One patient had a remote history of Hodgkin's lymphoma.
  • Thyroid fine-needle aspiration was performed before thyroidectomy in all cases; three of these cases contained some atypical cells, raising the possibility of Hodgkin's lymphoma.
  • Histologically, all cases were classical Hodgkin's lymphoma, nodular sclerosis subtype.
  • The four patients with primary thyroid lymphoma had Stage IIE disease.
  • A review of the English literature between 1962 and 2005 revealed 16 cases of thyroid Hodgkin's lymphoma, with a female preponderance and generally favorable outcome similar to the cases in our series.
  • Hodgkin's lymphoma of the thyroid is rare and can mimic a primary thyroid epithelial tumor or thyroiditis clinically.
  • Hodgkin's lymphoma should be considered in the differential diagnosis of thyroid neoplasms.
  • [MeSH-major] Hodgkin Disease / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Chronic Disease. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hypothyroidism. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Sclerosis / pathology. Thyroidectomy. Thyroiditis. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258502.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Gupta AK, Meisner D, Talreja N, Smith R, Swerdlow SH: Classical nodular sclerosis Hodgkin lymphoma presenting with central nervous system disease. South Med J; 2007 May;100(5):549-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical nodular sclerosis Hodgkin lymphoma presenting with central nervous system disease.
  • [MeSH-major] Brain Neoplasms / pathology. Cauda Equina / pathology. Hodgkin Disease / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534105.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


75. Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, Little AM, Ekstrom-Smedby K, Adami HO, Glimelius B, Hamilton-Dutoit S, Kane E, Taylor GM, McConnachie A, Ryder LP, Sundstrom C, Andersen PS, Chang ET, Alexander FE, Melbye M, Jarrett RF: HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A; 2010 Apr 06;107(14):6400-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.
  • A proportion of classical Hodgkin lymphoma (HL) is believed to be causally related to infection with the ubiquitous lymphotropic EBV.
  • To study the host genetic component of EBV-related HL further, we investigated the lymphoma's association with HLA-A*01 and HLA-A*02 simultaneously in the setting of infectious mononucleosis (IM), a risk factor for EBV-related HL, in a case-series analysis including 278 EBV-related and 656 EBV-unrelated cases of HL.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / immunology. HLA-A Antigens / genetics. Hodgkin Disease / genetics. Infectious Mononucleosis / genetics. Infectious Mononucleosis / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alleles. Female. Humans. Male. Middle Aged. Risk Factors. Young Adult


76. van Agthoven M, Kramer MH, Sonneveld P, van der Hem KG, Huijgens PC, Wijermans PW, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A: Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica; 2005 Oct;90(10):1422-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: We assessed direct health care costs associated with the most commonly prescribed treatments for indolent follicular non-Hodgkin's lymphoma (FL).
  • Classical FL treatments were found to be the least expensive treatments used with an estimated cost for cylophosphamide, vincristine and prednisone of 5,268 euro (2,644; n=58), for radiotherapy of 4,218 euro (4,313; n=52), and for chlorambucil of 2,476 euro (1,098; n=53).
  • [MeSH-major] Lymphoma, Follicular / economics. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / economics. Costs and Cost Analysis / economics. Female. Health Care Costs. Hospital Costs. Humans. Lymphoma, Non-Hodgkin / economics. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Netherlands. Retrospective Studies. Stem Cell Transplantation / economics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219580.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, Alonso MA, Pohlman B: MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol; 2006 May;125(5):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
  • Classical Hodgkin lymphoma (cHL) and mediastinal (thymic) large B-cell lymphoma (MLBL) have clinical, histopathologic, and molecular genetic similarities.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Membrane Transport Proteins / metabolism. Myelin Proteins / metabolism. Proteolipids / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / therapy. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707382.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  •  go-up   go-down


78. Schmidt A, Schmitz R, Giefing M, Martin-Subero JI, Gesk S, Vater I, Massow A, Maggio E, Schneider M, Hansmann ML, Siebert R, Küppers R: Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer; 2010 Sep;49(9):803-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.
  • Survival of the malignant Hodgkin and Reed/Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is dependent on constitutive activation of the nuclear factor kappaB (NF-kappaB) transcription factor.
  • [MeSH-major] Hodgkin Disease / genetics. Mutation / genetics. Reed-Sternberg Cells / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA Copy Number Variations. DNA-Binding Proteins. Female. Gene Expression Profiling. Humans. I-kappa B Proteins / genetics. I-kappa B Proteins / metabolism. In Situ Hybridization, Fluorescence. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Lasers. Male. Microdissection. Middle Aged. NF-kappa B / antagonists & inhibitors. NF-kappa B / genetics. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20607853.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CYLD protein, human; 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 139874-52-5 / NF-kappaB inhibitor alpha; EC 6.3.2.19 / TNFAIP3 protein, human
  •  go-up   go-down


79. Asano N, Suzuki R, Matsuo K, Kagami Y, Ishida F, Tamaru JI, Jin GS, Sato Y, Shimoyama Y, Yoshino T, Morishima Y, Nakamura S: Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology; 2007 May;50(6):705-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.
  • AIMS: The Revised European American Lymphoma classification uses the term Hodgkin's-like anaplastic large cell lymphoma (HD-like ALCL) for borderline cases with features of both anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (HL).
  • METHODS AND RESULTS: Subjects were 59 patients with HD-like ALCL, defined by nodal presentation without mediastinal bulky lesions, T- or null-cell phenotype, CD30+ anaplastic lymphoma kinase (ALK)- phenotype and by confluent sheets or nodules of large cells mimicking classic Hodgkin and Reed-Sternberg cells.
  • [MeSH-major] Granzymes / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Poly(A)-Binding Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Hodgkin Disease / pathology. Humans. Lymphocytes, Null / pathology. Male. Middle Aged. Phenotype. Predictive Value of Tests. Prognosis. Reed-Sternberg Cells / pathology. Survival Analysis. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Histopathology. 2007 Jun;50(7):962
  • (PMID = 17493234.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / Granzymes
  •  go-up   go-down


80. de Leval L, Hasserjian RP: Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am; 2009 Aug;23(4):791-827
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas and burkitt lymphoma.
  • Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children.
  • These changes include the addition of variants and subgroups of DLBCLs and "borderline" categories for high-grade B-cell neoplasms that show features intermediate between DLBCL and classical Hodgkin lymphoma, or between DLBCL and BL.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Antigens, CD5 / immunology. Child. Diagnosis, Differential. Humans. Immunophenotyping. World Health Organization

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577170.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5
  • [Number-of-references] 162
  •  go-up   go-down


81. Wilson KS, Freeland JM, Gallagher A, Cosby SL, Earle JA, Alexander FE, Taylor GM, Jarrett RF: Measles virus and classical Hodgkin lymphoma: no evidence for a direct association. Int J Cancer; 2007 Jul 15;121(2):442-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measles virus and classical Hodgkin lymphoma: no evidence for a direct association.
  • A proportion of Hodgkin lymphoma (HL) cases are causally associated with the Epstein-Barr virus (EBV) but the aetiology of the remaining cases remains obscure.
  • Over the last 3 decades several studies have found an association between HL and measles virus (MV) including a recent cohort study describing the detection of MV antigens in Hodgkin and Reed-Sternberg cells, the tumour cells in HL.
  • [MeSH-major] Hodgkin Disease / virology. Measles / virology. Measles virus / growth & development
  • [MeSH-minor] Adolescent. Adult. Animals. Case-Control Studies. Cell Line, Tumor. Cercopithecus aethiops. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / virology. Male. Middle Aged. Odds Ratio. RNA, Viral / genetics. RNA, Viral / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vero Cells. Viral Proteins / metabolism


82. Akhtar SS, Haque IU, Wafa SM, El-Saka H, Saroor AM, Nadrah HM: Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification. Saudi Med J; 2009 May;30(5):677-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification.
  • OBJECTIVE: To determine the frequency of various types of malignant lymphoma (ML) in the Al-Qassim region of Kingdom of Saudi Arabia (KSA) according to recently introduced the WHO classification.
  • RESULTS: Out of 385 cases reviewed, 251 (65.2%) had non-Hodgkin lymphoma (NHL) and 117 (30.4%) had Hodgkin lymphoma (HL).
  • B cell neoplasms were the most common NHL seen (81.6%) and diffuse large B cell lymphoma (DLBCL) was the most frequent type of NHL encountered (50.1%).
  • Indolent lymphomas like follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) were rather uncommon (13.2%).
  • T cell lymphoma comprised 18.3% of the NHL.
  • The most common type of HL was nodular sclerosis classical Hodgkin lymphoma (NSCHL) (68.3%).
  • [MeSH-major] Lymphoma / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Saudi Arabia. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417969.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


83. Jain S, Nigam S, Kumar N, Reddy BS: Cutaneous relapse in Hodgkin's disease: a case report. Acta Cytol; 2005 Mar-Apr;49(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous relapse in Hodgkin's disease: a case report.
  • BACKGROUND: Skin involvement in Hodgkin's disease is rare, can be seen in advanced stages of the disease and indicates a poor prognosis.
  • Smears from the lymph nodes showed classical Reed-Sternberg cells in a polymorphous background.
  • The cytologic diagnosis of Hodgkin's lymphoma was entertained and later confirmed on skin biopsy.
  • Past history revealed that the patient had been diagnosed with Hodgkin's disease and treated for it 2 years earlier, but had been lost to follow-up during treatment.
  • CONCLUSION: Cutaneous Hodgkin's disease should always be considered in smears from skin lesions showing atypical mononuclear cells in a polymorphous background, even in the absence of a definitive clinical diagnosis at the time of presentation.
  • [MeSH-major] Hodgkin Disease / pathology. Skin / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Biopsy, Needle. Disease Progression. Drug Therapy. Humans. Leukocytes, Mononuclear / pathology. Lymph Nodes / pathology. Male. Prognosis. Recurrence

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839627.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ: Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med; 2006 Oct;130(10):1497-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pleural involvement by lymphoma is relatively common.
  • DESIGN: We reviewed the clinicopathologic features of 34 patients with lymphoma involving the pleura proven by biopsy and classified these neoplasms using the World Health Organization classification.
  • Eighteen (56.2%) of 32 patients with adequate clinical data had a history of lymphoma (including 3 patients with pleural involvement as the only disease site).
  • In 29 (85.3%) cases, a specific diagnosis according to the World Health Organization classification could be made: 17 (58.6%) diffuse large B-cell lymphoma, 5 (17.2%) follicular lymphoma (including a case with areas of diffuse large B-cell lymphoma), 2 (6.9%) small lymphocytic lymphomas/chronic lymphocytic leukemia, 2 (6.9%) precursor T-cell lymphoblastic lymphoma/leukemia, 1 (3.4%) mantle cell lymphoma, 1 (3.4%) posttransplant lymphoproliferative disorder, and 1 (3.4%) classical Hodgkin lymphoma.
  • Cytologic examination of pleural fluid was performed in 15 cases and was positive for lymphoma in 8 (53.3%) cases.
  • CONCLUSIONS: Most patients with lymphoma involving the pleura have simultaneous evidence of systemic involvement.
  • The most frequent type is diffuse large B-cell lymphoma, followed by follicular lymphoma.
  • Cytologic examination can have negative results in patients with pleural involvement by lymphoma.
  • [MeSH-major] Lymphoma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Body Fluids / cytology. Female. Humans. Immunophenotyping. Incidence. Lymphoma, B-Cell / epidemiology. Lymphoma, Follicular / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Medical Records. Middle Aged. Neoplasms, Second Primary / pathology. Retrospective Studies. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090191.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Herling M, Rassidakis GZ, Vassilakopoulos TP, Medeiros LJ, Sarris AH: Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood; 2006 Feb 1;107(3):1240; author reply 1241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Gene Expression Regulation, Viral. Hodgkin Disease / metabolism. Viral Matrix Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • (PMID = 16434497.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


86. Flangea C, Potencz E, Mihăescu R, Anghel A, Gîju S, Motoc M, Dogaru C: CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging. Rom J Morphol Embryol; 2006;47(2):113-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
  • INTRODUCTION: The presence of Reed-Sternberg malignant cells is absolutely necessary for Hodgkin's lymphoma diagnostic, but it is not always sufficient because can be observed Reed-Sternberg-like cells in other malignant and benign diseases, too.
  • The CD30 expression at Hodgkin and Reed-Sternberg level can give us supplementary information in differential diagnostic and can be used as progressive disease factor.
  • MATERIAL AND METHODS: Our study was composed from 63 cases histopathological diagnosed with Hodgkin's lymphoma and hospitalized in Hematology Department of County Hospital Timişoara.
  • We consider that using this staining, although less used in Romania, must be done in all Hodgkin's lymphoma and Hodgkin's lymphoma-like cases.
  • [MeSH-major] Antigens, CD30 / immunology. Hodgkin Disease / immunology. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / immunology. Child. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Reed-Sternberg Cells / immunology. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106517.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30
  •  go-up   go-down


87. Zhang JR, Raza AS, Greaves TS, Cobb CJ: Fine-needle aspiration diagnosis of Hodgkin lymphoma using current WHO classification--re-evaluation of cases from 1999-2004 with new proposals. Diagn Cytopathol; 2006 Jun;34(6):397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration diagnosis of Hodgkin lymphoma using current WHO classification--re-evaluation of cases from 1999-2004 with new proposals.
  • With the advent of modern therapy, the differences in prognoses and treatment regimens among different subtypes of Hodgkin lymphoma (HL) have largely vanished.
  • The current (2001) WHO classification markedly de-emphasizes spatial relationships as critical to the diagnosis of lymphoma and emphasizes cell morphology, immunophenotype, genetic features, and clinical information to define the disease states.
  • For the 22 suspicious cases, 13 were HL (59.1%), 5 were other lymphomas (22.8%), 1 was lymphoma unclassifiable (4.5%), and 3 were reactive processes (13.6%).
  • (1) If the FNA diagnosis of HL is confirmed both by morphology and immunostains, no further tissue confirmation, subclassification and grading is necessary, and appropriate treatment regimens should follow. (2) The nodular lymphocyte predominant HL and classical HL can be differentiated by adequate immunostaining. (3) If a definitive diagnosis cannot be achieved by FNA, a second FNA or a tissue biopsy should be recommended.
  • [MeSH-major] Biopsy, Fine-Needle. Hodgkin Disease / classification. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680774.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA: High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol; 2007 Jun;137(6):553-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
  • As Hodgkin and Reed-Sternberg (HRS) cells express receptors through which BLyS promotes their growth and chemotherapy resistance, we investgated whether this molecule was increased in sera from patients with classical Hodgkin lymphoma (cHL) and whether it correlates with clinical-pathological features and outcomes.
  • [MeSH-major] B-Cell Activating Factor / blood. Biomarkers, Tumor / blood. Hodgkin Disease / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539776.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Adams H, Campidelli C, Dirnhofer S, Pileri SA, Tzankov A: Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets; 2009 Oct;13(10):1137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
  • OBJECTIVE: Post-transplant Hodgkin lymphoma (ptHL) is a rare but serious complication.
  • We explored the clinical, phenotypic and genetic similarities and disparities between ptHL and classical Hodgkin lymphoma (cHL) in immunocompetent patients and sought proteins/pathways in ptHL that might have potential as therapeutic targets.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Hodgkin Disease / chemically induced. Hodgkin Disease / genetics. Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / genetics. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Kidney Transplantation. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705967.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


90. Lawrie CH, Marafioti T, Hatton CS, Dirnhofer S, Roncador G, Went P, Tzankov A, Pileri SA, Pulford K, Banham AH: Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. Int J Cancer; 2006 Jun 15;118(12):3161-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
  • We used carbohydrate array technology to compare serum antibody (IgG and IgM) levels against 37 different carbohydrates between classical Hodgkin's lymphoma (cHL) patients and age/sex-matched healthy controls.
  • Serum IgM levels measured by ELISA against 2 of the 5 carbohydrates identified using this technique, L-alpha-arabinose (L-Araf) and alpha-N-acetylgalactosamine (GalNAc(alpha)), were higher (F values of 11.30 and 18.27, respectively) in a cohort of cHL patients (n = 16) than either diffuse large B-cell lymphoma patients (n = 18) or control sera (n = 12).
  • Tn was expressed in 41/238 (17%) classical HL cases present on a tissue microarray.
  • [MeSH-major] Carbohydrates / blood. Hodgkin Disease / blood
  • [MeSH-minor] Acetylgalactosamine / blood. Adaptor Proteins, Signal Transducing. Adult. Aged. Antigens, CD79 / blood. Arabinose / blood. Case-Control Studies. Cyclin-Dependent Kinase Inhibitor p27 / blood. Cytoskeletal Proteins. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / blood. LIM Domain Proteins. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16395706.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD79; 0 / Carbohydrates; 0 / Cytoskeletal Proteins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / PDLIM7 protein, human; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; B40ROO395Z / Arabinose; KM15WK8O5T / Acetylgalactosamine
  •  go-up   go-down


91. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV, Bhagat G: Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol; 2007 Feb;38(2):315-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We thus performed cytogenetic analysis of 28 cases of B-cell PTLD, 1 infectious mononucleosis (IM)-like lesion, 9 polymorphic PTLD, 17 monomorphic PTLD, and 1 classical Hodgkin lymphoma (HL), and correlated the karyotypic findings with the phenotype, Epstein-Barr virus infection status, and clinical outcome.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Chromosome Banding. Clone Cells / metabolism. Clone Cells / pathology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / virology. Female. Genotype. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Karyotyping. Liver Transplantation / adverse effects. Male. Middle Aged. Organ Transplantation / adverse effects. Phenotype. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134734.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Mani H, Jaffe ES: Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma; 2009 Jun;9(3):206-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma: an update on its biology with new insights into classification.
  • In the past few years, there has been a greater understanding of the spectrum and biology of Hodgkin lymphoma (HL).
  • In standard texts, HL is classified as 2 distinct entities, namely nodular lymphocyte-predominant HL and classical HL (CHL).
  • Nodular sclerosis HL might also be related to primary mediastinal B-cell lymphoma and mediastinal gray-zone lymphomas.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Cytokines / metabolism. Female. Genetic Predisposition to Disease. HIV Infections / metabolism. Herpesvirus 4, Human / metabolism. Humans. Immunophenotyping. Lymphocytes / metabolism. Lymphoma, B-Cell / metabolism. Male. Social Class

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3108-13 [10556196.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):387-94 [10637283.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1041-52 [15078899.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):780-4 [15150306.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] Blood. 1999 Jul 15;94(2):411-6 [10397707.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3122-7 [10506608.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:184-202 [15561683.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Blood. 2000 May 15;95(10):3020-4 [10807764.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • [Cites] Isr Med Assoc J. 2000 Jul;2(7):501-3 [10979320.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):297-306 [11224599.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Hematol Oncol. 2001 Mar;19(1):1-17 [11276042.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] Histopathology. 2001 Apr;38(4):368-75 [11318902.001]
  • [Cites] Blood. 2001 May 15;97(10):3191-6 [11342448.001]
  • [Cites] Blood. 2001 Jul 1;98(1):194-200 [11418480.001]
  • [Cites] Blood. 2001 Aug 1;98(3):762-70 [11468177.001]
  • [Cites] Mol Med. 2001 May;7(5):285-92 [11474574.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Blood. 2002 Jan 15;99(2):690-3 [11781255.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):585-96 [11839579.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):216-23 [11869895.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1141-7 [14614054.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):1-9 [14962256.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):103-13 [16949642.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):875-9 [17131320.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):609-11 [15160926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1236-43 [15247136.001]
  • [Cites] Acta Haematol. 2004;112(3):129-35 [15345894.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1375-84 [15359636.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Bull Hist Med. 1969 Mar-Apr;43(2):138-75 [4890530.001]
  • [Cites] Bull N Y Acad Med. 1970 Jan;46(1):67-9 [4903331.001]
  • [Cites] Int J Cancer. 1971 Sep 15;8(2):192-201 [5133848.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Am J Pathol. 1977 Apr;87(1):19-32 [322504.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1979;31(3):211-25 [43015.001]
  • [Cites] Ann Intern Med. 1980 May;92(5):587-95 [6892984.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Immunol Rev. 1983;70:167-92 [6403456.001]
  • [Cites] Br J Cancer. 1983 May;47(5):707-12 [6849804.001]
  • [Cites] Am J Clin Pathol. 1984 Dec;82(6):666-73 [6391148.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1150-3 [2917317.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1686-93 [2790683.001]
  • [Cites] J Natl Cancer Inst. 1990 May 16;82(10):855-8 [2185367.001]
  • [Cites] N Engl J Med. 1992 Apr 23;326(17):1115-22 [1532439.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):252-8 [1599017.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S21-4 [9926233.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] N Engl J Med. 1999 Apr 22;340(16):1239-47 [10210707.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3964-72 [10339506.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1685-91 [10362793.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):90-6 [15389259.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):127-34 [15632006.001]
  • [Cites] J Pathol. 2005 Apr;205(5):541-7 [15732141.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):167-71 [15796964.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):199-205 [15813847.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):26-33 [16007865.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5052-60 [15955904.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):661-6 [15875183.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:231-8 [16304386.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2360-2 [16224482.001]
  • [Cites] Cell Signal. 2006 Apr;18(4):449-55 [15967637.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):7 [16391364.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):495-501 [16396774.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] J Pathol. 2006 Feb;208(3):423-30 [16353293.001]
  • [Cites] Expert Opin Ther Targets. 2006 Feb;10(1):27-35 [16441226.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):567-72 [11920617.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:11-8 [12078890.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:44-51 [12078902.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:75-8 [12078907.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4908-20 [12118370.001]
  • [Cites] J Pathol. 2002 Nov;198(3):310-6 [12375263.001]
  • [Cites] Immunity. 2002 Oct;17(4):473-85 [12387741.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1813-8 [12685837.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Int J Hematol. 2003 May;77(4):330-5 [12774919.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):843-58 [12852658.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):706-12 [12866030.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):126-36 [12939740.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):206-13 [12966346.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2214-9 [14523479.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3434-40 [16868249.001]
  • [Cites] Pathobiology. 2006;73(3):107-25 [17085956.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Clin Pathol. 2007 Oct;60(10):1092-7 [17158640.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1252-7 [18594468.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] Arch Pathol Lab Med. 1992 Sep;116(9):969-72 [1524465.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):859-67 [1384376.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):123-32 [8422110.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1595-602 [8123850.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):526-30 [8172327.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Ann Oncol. 1995 May;6(5):477-82 [7545429.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1294-9 [7573692.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):179-83 [8603808.001]
  • [Cites] Blood. 1996 May 1;87(9):3844-51 [8611711.001]
  • [Cites] Leukemia. 1996 May;10(5):829-35 [8656679.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1279-87 [8827036.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):538-42 [8849727.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Immunol Today. 1997 Apr;18(4):156-63 [9136451.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:79-81 [9209647.001]
  • [Cites] Pathology. 1997 Aug;29(3):294-9 [9271021.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):229-35 [9520936.001]
  • [Cites] Blood. 1998 Aug 1;92(3):790-4 [9680346.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1272-6 [9697883.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Immunol Lett. 2006 Apr 15;104(1-2):83-8 [16386314.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Trends Immunol. 2006 May;27(5):203-5 [16563865.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):776-82 [16707382.001]
  • [Cites] Yale J Biol Med. 2005 Jul;78(4):203-10 [16720015.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):398-403 [16787869.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):352-60 [16770772.001]
  • [Cites] Acta Haematol. 2006;116(2):101-7 [16914904.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2037-49 [16919769.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1518-22 [16966262.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):552-8 [17006259.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1844-51 [16983704.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1863-71 [17064999.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Tumour Biol. 2006;27(6):329-33 [17033203.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2115-27 [17071485.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10332-8 [17079453.001]
  • (PMID = 19525189.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC011070-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 204
  • [Other-IDs] NLM/ NIHMS161993; NLM/ PMC2806063
  •  go-up   go-down


93. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD: Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood; 2010 Jul 22;116(3):418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.
  • In classical Hodgkin lymphoma (cHL) the mechanisms underlying primary refractory disease and relapse remain unknown.
  • [MeSH-major] Gene Dosage. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Child. Chromosomes, Human, Pair 16 / genetics. Comparative Genomic Hybridization. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Multidrug Resistance-Associated Proteins / antagonists & inhibitors. Multidrug Resistance-Associated Proteins / genetics. RNA, Small Interfering / genetics. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Jul 22;116(3):309-11 [20651079.001]
  • (PMID = 20339089.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / 178536
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Small Interfering; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


94. Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL: Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control; 2009 Dec;20(10):1881-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparities in survival after Hodgkin lymphoma: a population-based study.
  • Survival after Hodgkin lymphoma (HL) is generally favorable, but may vary by patient demographic characteristics.
  • For 12,492 classical HL patients ≥ 15 years diagnosed in California during 1988-2006 and followed through 2007, we determined risk of overall and HL-specific death using Cox proportional hazards regression; analyses were stratified by age and Ann Arbor stage.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 2001 Feb;55(2):111-22 [11154250.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):384-9 [10708941.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1306-15 [11423262.001]
  • [Cites] Tissue Antigens. 2001 May;57(5):424-39 [11556967.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):803-12 [11714108.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):39-46 [12115315.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] MMWR Surveill Summ. 2003 Aug 22;52(8):1-80 [14532868.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(12):2265-79 [14572836.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):27-33 [14695846.001]
  • [Cites] Eur J Haematol. 2004 Nov;73(5):318-24 [15458510.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Am J Public Health. 1981 Mar;71(3):242-50 [7468855.001]
  • [Cites] J Natl Cancer Inst. 1987 Mar;78(3):471-8 [3469461.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1285-92 [3411341.001]
  • [Cites] Public Health Rep. 1990 Jul-Aug;105(4):361-7 [2116637.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1500-9 [2072149.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1254-8 [1739924.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):560-5 [8426624.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):602-6 [8319194.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2918-29 [8639912.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12):1020-6 [9867756.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1413-9 [15603866.001]
  • [Cites] Oncol Nurs Forum. 2005 Mar;32(2):250-6 [15759063.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1441-7 [15941953.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):14-20 [16007863.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):125-34 [16007881.001]
  • [Cites] JAMA. 2005 Oct 12;294(14):1765-72 [16219879.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Clin Lab Haematol. 2005 Dec;27(6):379-83 [16307539.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):5-19 [16143594.001]
  • [Cites] Cancer Causes Control. 2006 Aug;17(6):771-81 [16783605.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):875-9 [17131320.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(14):2058-73 [18657412.001]
  • [Cites] CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31 [18096863.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):177-87 [17219013.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2244-55 [10561282.001]
  • [Cites] Med Care. 2001 Apr;39(4):361-72 [11329523.001]
  • (PMID = 19557531.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA117454-01; United States / NCI NIH HHS / CA / R03 CA117454; United States / PHS HHS / / #U55/CCR921930-02; United States / NCI NIH HHS / PC / N01 PC035136-21-0-0; None / None / / N01 PC035136-21-0-0; United States / NCI NIH HHS / CA / CA117454-01; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S: HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol; 2007 Jul 20;25(21):3101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
  • PURPOSE: The neoplastic Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL) are derived from B cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cause of Death. Histocompatibility Antigens Class II / analysis. Hodgkin Disease / immunology. Hodgkin Disease / mortality. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Prognosis. Proportional Hazards Models. Registries. Risk Assessment. Sensitivity and Specificity. Severity of Illness Index. Sex Factors. Survival Analysis

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


96. Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E: Mycosis fungoides associated with B-cell malignancies. Br J Dermatol; 2006 Aug;155(2):379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The coexistence of mycosis fungoides, a peripheral T-cell lymphoma, and B-cell malignancies or Hodgkin's lymphoma in the same patient is unusual.
  • OBJECTIVES: To detect cases of mycosis fungoides associated with B-cell malignancies or Hodgkin's lymphoma and to analyse the characteristics of and the interplay between the lymphoproliferative neoplasms.
  • METHODS: Patients with mycosis fungoides who had B-cell malignancies or Hodgkin's lymphoma were selected from among 398 patients either treated or followed up in two tertiary medical centres during a 7-year period.
  • RESULTS: Eleven patients with mycosis fungoides and B-cell malignancy were detected (seven of non-Hodgkin's lymphoma, three of chronic lymphocytic leukaemia, one of multiple myeloma).
  • No case of Hodgkin's lymphoma was found.
  • Two patients who presented with early-stage mycosis fungoides (IA) as the first lymphoma developed mycosis fungoides tumours after becoming immunosuppressed.
  • One showed two distinct populations of the malignant cells in the skin tumour, thus constituting a classical composite lymphoma of mycosis fungoides and chronic lymphocytic leukaemia, while in the other patient the two malignant populations of marginal B-cell lymphoma and mycosis fungoides (as evidenced by both phenotypic and genotypic findings) were intermingled.
  • CONCLUSIONS: This case series indicates that while the coexistence of Hodgkin's lymphoma and mycosis fungoides is extremely rare, the association of mycosis fungoides and B-cell malignancies is not as rare as reflected in the literature, with non-Hodgkin's lymphoma constituting the most common associated B-cell malignancy.
  • It is suggested that for greater precision the criteria for diagnosis of composite lymphoma of the skin should include both phenotypic and genotypic features.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Male. Middle Aged


97. Kleger A, Bommer M, Kunze M, Klaus J, Leithaeuser F, Wegener M, Adler G, Dikopoulos N: First reported case of disease: peliosis hepatis as cardinal symptom of Hodgkin's lymphoma. Oncologist; 2009 Nov;14(11):1088-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First reported case of disease: peliosis hepatis as cardinal symptom of Hodgkin's lymphoma.
  • Further evaluation of our patient with an x-ray and a computed tomography (CT) scan revealed a mediastinal mass and a CT-guided biopsy showed classical Hodgkin's lymphoma.
  • After completing further screening, a definitive diagnosis of Hodgkin's lymphoma stage II/N/B (Ann-Arbor) was established and chemotherapy according to the German Hodgkin's study group protocol with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (the BEACOPP regimen) was initiated.
  • Taken together, we present the case of a patient with peliosis hepatis as an uncommon manifestation of Hodgkin's lymphoma.
  • Despite an extensive literature search, we could not find any case of peliosis hepatis associated with a de novo diagnosis of classical Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiography. Peliosis Hepatis / radiography
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Humans. Prednisone / administration & dosage. Procarbazine / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889716.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


98. Flangea C, Potencz E, Mihăescu R, Gîju S, Anghel A: Bcl-2 expression in Hodgkin's lymphoma progression. Rom J Morphol Embryol; 2008;49(3):357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in Hodgkin's lymphoma progression.
  • INTRODUCTION: Hodgkin's lymphoma study by immunohistochemical expression of Bcl-2 in Hodgkin and Reed-Sternberg cells can precise these cases evolutive way.
  • MATERIAL AND METHODS: Sixty-three cases of classical Hodgkin's disease, hospitalized into the Hematology Department of the County Hospital No. 1 Timisoara, were studied.
  • No connection we can be noticed between the histological type and Bcl-2 expression although the classic Hodgkin's lymphoma with lymphocyte depletion is considered the most aggressive histological type (p < or = 1).
  • [MeSH-major] Hodgkin Disease / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Disease Progression. Humans. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758641.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


99. Faris JE, LaCasce AS: Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol; 2009 Feb;7(2):125-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma, which has distinct clinical and molecular features, many of which are similar to that of nodular sclerosing/classical Hodgkin lymphoma.
  • Anthracycline-based chemotherapy forms the foundation for treatment of this lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mediastinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Gene Expression Profiling. Humans. Male. Prednisolone / administration & dosage. Randomized Controlled Trials as Topic. Rituximab. Sex Distribution. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367254.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


100. Chetaille B: [Mediastinal lymphomas: histopathology]. Rev Pneumol Clin; 2010 Feb;66(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three main entities summarize this pathology: T lymphoblastic lymphoma, mediastinal (thymic) diffuse large B cell lymphoma, and classical Hodgkin lymphoma.
  • Their diagnosis is usually performed on tissue collected by mediastinoscopy and requires the implementation of techniques such as classical histopathology, immunohistochemistry, and sometimes molecular biology.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Child. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Mediastinum / pathology. Mediastinum / surgery. Neoplasm Invasiveness. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prognosis. Thymus Neoplasms / diagnosis. Thymus Neoplasms / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Masson SAS.
  • (PMID = 20207293.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 2
  •  go-up   go-down






Advertisement